

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Asplenic patients' and doctors' experiences in implementing preventative measures following a novel educational intervention: a qualitative analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-060492
Article Type:	Original research
Date Submitted by the Author:	22-Dec-2021
Complete List of Authors:	Anka, Natascha; University of Freiburg Faculty of Medicine, Section of Health Care Research and Rehabilitation Research Glattacker, Manuela ; University of Freiburg Faculty of Medicine, Section of Health Care Research and Rehabilitation Research Farin, Erik; University of Freiburg Faculty of Medicine, Section of Health Care Research and Rehabilitation Research Camp, Johannes; University of Freiburg Faculty of Medicine, Division of Infectious Diseases, Department of Medicine II Rieg, Siegbert; University of Freiburg Faculty of Medicine, Division of Infectious Diseases, Department of Medicine II Bayrhuber, Marianne; University of Freiburg Faculty of Medicine, Section of Health Care Research and Rehabilitation Research
Keywords:	PREVENTIVE MEDICINE, QUALITATIVE RESEARCH, INFECTIOUS DISEASES, MEDICAL EDUCATION & TRAINING

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 1 **Asplenic patients' and doctors' experiences in implementing preventative measures**
4
5 2 **following a novel educational intervention: a qualitative analysis**
6

7 3
8
9 4 Natascha Anka^{1*}: natascha.anka@uniklinik-freiburg.de

10
11 5 PD Dr. Manuela Glattacker¹: manuela.glattacker@uniklinik-freiburg.de

12
13 6 Prof. Dr. Erik Farin-Glattacker¹: erik.farin@uniklinik-freiburg.de

14
15 7 Dr. Johannes Camp²: johannes.camp@uniklinik-freiburg.de

16
17 8 Prof. Dr. Siegbert Rieg²: siegbert.rieg@uniklinik-freiburg.de

18
19 9 Dr. Marianne Bayrhuber¹: marianne.bayrhuber@uniklinik-freiburg.de
20
21

22 10

23
24 11 *First author
25
26 12

27
28 13 ¹ Section of Health Care Research and Rehabilitation Research, Faculty of Medicine,
29
30 University of Freiburg, Freiburg, Germany

31
32 15 ² Division of Infectious Diseases, Department of Medicine II, Medical Center – Faculty of
33
34 Medicine, University of Freiburg, Freiburg, Germany
35
36 17

37
38
39 18 **Corresponding author**

40
41 19 Dr. Marianne Bayrhuber

42
43 20 Section of Health Care Research and Rehabilitation Research

44
45 21 Faculty of Medicine, University of Freiburg

46
47 22 Hugstetter Straße 49

48
49 23 79106 Freiburg

50
51 24 Germany

52
53 25 Phone: +49 761 270 83734

54
55 26 E-Mail: marianne.bayrhuber@uniklinik-freiburg.de
56
57 27

58
59 28 Word count (excluding title page, abstract, references, figures and tables): 4656
60

29 ABSTRACT

30 **Objective:** To explore asplenic patients' and GPs' (1) perceptions of a novel, *Health Action*
31 *Process Approach* (HAPA)-based, educational intervention which targets to increase
32 adherence to post-splenectomy sepsis (PSS) prevention measures and (2) their experience in
33 implementing prevention measures following this intervention.

34 **Design:** A process evaluation conducted on average 3.5 (for patients) and 3.8 (for GPs)
35 months after the intervention between January 2020 and April 2021 individually by means of
36 semi-structured guideline-based telephone-interviews. Data was analysed using qualitative
37 content analysis.

38 **Participants:** Volunteer sub-sample of N = 25 asplenic patients and N = 8 GPs who received
39 the intervention. Inclusion criteria were met by prior participation in the intervention (German-
40 speaking, of full age and insured by the cooperating health insurance). Patient selection was
41 done by purposeful selection aiming at maximum variability in terms of adherence to
42 preventative measures prior to intervention participation. Participating GPs are a non-
43 purposeful selected convenience sample. For reasons of data protection, no personal data
44 was collected.

45 **Results:** The intervention was positively evaluated and its personal relevancy for patients and
46 for the GPs' professional work became apparent. The intervention promoted risk awareness,
47 intention to action, action planning and subsequently, improved adherence to preventative
48 measures. Helpful factors for implementation among the patients were social support by
49 relatives and GPs. Barriers to adherence identified in both groups can be divided into patient-
50 attributed (e.g. comorbidities), doctor-related (e.g. lack of knowledge or support) as well as
51 contextual factors (e.g. vaccine supply constraints).

52 **Conclusions:** Our findings indicate a patient and GP perceived benefit of the intervention, but
53 still identify prevailing barriers to implementation. In a further step, a quantitative evaluation of
54 the intervention will be conducted and recommendations for integrating the intervention in
55 usual care will be made.

1
2
3 56 **Trial registration:** German Clinical Trials Register (DRKS): DRKS00015238; Trial registration
4
5 57 date is 7th December 2018.
6
7 58

9 59 **Keywords:** Asplenia, Post-splenectomy sepsis (PSS), Sepsis, Splenectomy, General
10
11 60 practitioners (GPs), Prevention, Intervention, Health Action Process Approach (HAPA),
12
13 61 Interviews, Qualitative Content Analysis, Barriers
14
15
16
17

18 62 **Article Summary**

19
20 63 Strengths and limitations of this study

- 21
22 64 • This is the first study in the field of asplenia that explores in depth patients' and GPs'
23
24 65 experiences in implementation of PSS preventative measures following an intervention
25
26 66 intended to increase adherence.
27
28 67 • Purposeful selection of patients which aimed at maximum variation regarding their pre-
29
30 68 interventional adherence enabled to explore a sample with diverse initial experiences in
31
32 69 preventative behaviour.
33
34 70 • A minor limitation as regards to the intended maximum variation selection is that very high
35
36 71 levels of adherence did not occur in the sample.
37
38 72 • Since participation in the interview, which serves as the data basis in this study, was a
39
40 73 voluntary additional effort, a positive bias might have been induced.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

75 INTRODUCTION

76 Patients with an absent or dysfunctional spleen are susceptible to infectious diseases
77 throughout their lives and are at an increased risk of developing an post-splenectomy sepsis
78 (PSS; also called overwhelming post-splenectomy infection, abbr. OPSI)[1], with a mortality
79 rate up to 50%[2]. According to international clinical guidelines, OPSI is largely preventable
80 through prophylactic measures in this patient population[3]. These measures include amongst
81 others anti-pneumococcal and anti-meningococcal vaccination, permanent availability of a
82 medical alert card and an antibiotic supply for emergency fever treatment ('pill in the pocket')
83 as well as patient education.

84 However, there is widespread evidence, that guideline awareness and adherence are low[1].
85 Even if the doctor's knowledge and attitude towards guidelines was found to be appropriate,
86 patient education by health providers as well as inter-sectorial communication were described
87 as insufficient[4]. Thus, many asplenic patients have poor knowledge about the risk associated
88 with their condition and existing prevention recommendations[i.a. 5-7]. Beyond these
89 knowledge (transfer) gaps mainly reported in literature, barriers such as safety concerns,
90 scepticism and the doubted need for vaccination are further reasons that were found for
91 asplenic patients' non-adherence[8]. As better patient knowledge can be considered a key
92 factor in improving adherence[9], and primary care providers are critical in patient education
93 and prevention implementation[8, 10], we developed a novel educational intervention for both
94 asplenic patients and for their general practitioners (GPs) (for a detailed description of the
95 intervention see[11] or supplemental material).

96 The intervention is a manual-based individualised telephone counselling on evidence-based
97 information of the spleen, asplenia-related infection risks and infection prevention
98 recommendations, conducted by an infectious diseases specialist. The *Health Action Process*
99 *Approach* (HAPA), a framework that provides predictors for initiation and maintenance of
100 preventative behaviour[12], including vaccination behaviour[i.a. 13], served as theoretical
101 basis. Distinguished into two phases in the HAPA, these predictors include risk perception,
102 outcome expectancies and perceived task self-efficacy which influence the formation of an

1
2
3 103 intention (*motivational phase*) as well as action and barrier coping planning and maintenance
4
5 104 self-efficacy that lead to the actual behaviour (*volitional phase*). Accordingly, our intervention
6
7 105 includes specific components which promote motivation for initiation as well as action-related
8
9 106 strategies such as planning and managing barriers, the latter being realised through a
10
11 107 customisable action plan for patients. For doctors, the intervention is primarily information-
12
13 108 orientated by conveying current guideline recommendations for asplenic patients in general
14
15 109 and the attending patient specifically. Accompanying the telephone intervention, participants
16
17 110 receive written information tailored both to patient and doctor, along with a plain vaccination
18
19 111 schedule and a medical alert card.
20
21
22 112 The intervention is currently being evaluated in terms of its effectiveness in a two-armed
23
24 113 historical control-group design. Moreover, as recommended for complex interventions[14], the
25
26 114 intervention was evaluated in a qualitative process evaluation. The findings of the process
27
28 115 evaluation will be reported in the present article, the quantitative findings will be reported
29
30 116 elsewhere. The aim of the process evaluation is to investigate how patients and doctors
31
32 117 evaluate the intervention and how they perceive its usefulness for implementation, with
33
34 118 particular attention to health behaviour changing factors according to HAPA. And notably, the
35
36 119 objective is to gain a deeper understanding of the participants' experience in implementing the
37
38 120 preventative measures post-intervention, including factors that influence adherence, that are
39
40 121 subjectively perceived barriers as well as helpful factors.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

122 METHODS

123 **Study design**

124 This is a qualitative interview-study conducted with asplenic patients and attending GPs. The
125 methods are presented in accordance with the consolidated criteria for reporting qualitative
126 research (COREQ) checklist[15] (see supplemental material).

127 **Patient and public involvement**

128 Patients or the public were not actively involved in this research.

129 **Participants and recruiting**

130 The sample is a sub-sample of asplenic patient and doctor participants, who received the
131 intervention and were willing to take part in an additional interview (willingness was queried
132 after participation in the intervention on the phone). Inclusion criteria for patients were met by
133 prior study participation (these were German-speaking, of full age and insured by the
134 cooperating AOK health insurance; see[11]). All interviewees provided written informed
135 consent to participate, including having their interview audiotaped and further processed. They
136 received a 30 € voucher for participation. For reasons of data protection, no personal data was
137 collected.

138 Patient participants

139 Patients were selected using a maximum variation sampling approach (purposeful sampling).
140 A maximum variability in terms of their pre-interventional study-specific 'Preventing PSS-score'
141 ('PrePSS-score') was sought. The 'PrePSS-score' indicates patients' adherence to the
142 recommended preventative measures on a scale from 0 to 10 (anti-pneumococcal and anti-
143 meningococcal vaccination, availability of a medical alert card and of an antibiotic supply; for
144 details on development and calculation of the 'PrePSS-score' see[11]), with higher scores
145 indicating greater adherence. With this approach, we expected to explore diverse experiences
146 in implementation as those might differ according to prevention measures taken prior to the
147 study participation.

1
2
3 148 Selection was performed in two phases. Firstly, all the patients who had agreed to participate
4
5 149 were selected successively. After conducting initial N=14 interviews, further patients were
6
7 150 purposively selected in an iterative process on the basis of so far unrepresented or
8
9 151 underrepresented preinterventional 'PrePSS-score' to obtain maximum variation. Appropriate
10
11 152 maximisation was assumed when each possible 'PrePSS-score' (0-10) occurred at least twice.
12
13 153 Thus, this approach was also used to determine the minimum number of interviews necessary.
14
15 154 Since the values 7, 9 and 10 did not occur among patients who were willing to participate, the
16
17 155 range of variation was determined by the actual scores present for this sub-group (for exact
18
19 156 frequencies see table 1).
20
21
22 157 In total N=31 patients were contacted. As N=6 of them did not provide written consent (N=1
23
24 158 refused participation due to ongoing treatment, N=5 could not be reached), N=25 patients were
25
26 159 interviewed. That is 22.7% of all patients (N=110) who received the intervention.
27
28
29
30

31 161 Table 1 *Frequencies of the preinterventional 'PrePSS-score' of the participants*

PrePSS-score (0-10)	N	%
0	1	4
1	4	16
2	5	20
3	3	12
4	4	16
5	3	12
6	3	12
7	0	0
8	2	8
9	0	0
10	0	0

32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52 162

53
54
55 163 Doctor participants

56
57 164 Due to low participation willingness and difficulties with accessibility (presumably in part
58
59 165 because this study was conducted during the COVID-19-pandemic) a non-purposeful selection

1
2
3 166 procedure was required for the doctors. We took a convenience sample of doctors, i.e. all
4
5 167 those who were willing to participate (N=11) were contacted for study participation. Among
6
7 168 these, N=8 participated. The remaining N=3 participants were not reachable (N=2) or refused
8
9 169 participation due to lack of time (N=1). Participating doctors were the GPs of any of the
10
11 170 intervention group patients. Thus, patients and doctors were not chosen in pairs for the
12
13 171 interviews.
14
15

16 172

173 **Interview guideline**

174 The semi-structured interview guidelines for patients and doctors were drafted by N.A und M.B.
175 following Helfferich (2011)[16] and finalised after review by the whole study team. Marginal
176 adjustments to improve applicability were made upon mutual agreement between the
177 interviewers after 14 patient interviews were conducted.

178 The interview guide for patients was divided into three obligatory main blocks on the topics (a)
179 'evaluation of the telephone intervention' (initial question), (b) 'experience in implementing
180 preventative measures' and (c) 'dealing with sepsis risk' and (d) a supplementary block
181 addressing the written information material accompanying the telephone intervention. Each
182 question block contained an open-ended obligatory core question that subsumed the key
183 aspects of each topic. Interviewees were to be given the opportunity to freely report on their
184 experiences, specific questions were only posed if a relevant aspect of the core topic was not
185 proposed by the participants. The interview guide for doctors contained the topics (a)
186 'evaluation of telephone intervention' (initial question), (b) 'usefulness of the telephone
187 intervention' and (c) a question block addressing the written information material. Overall, the
188 doctor interview guide was more information-orientated compared to the patients' guide, and
189 improvement suggestions were directly requested from doctors. The interview guidelines are
190 attached as supplementary table 1 and 2.

191

192 **Procedure and transcription**

193 Patients and doctors were interviewed individually between January 2020 and April 2021 via
194 telephone by M.B. and N.A. using the developed guideline. M.B. and N.A., both female
195 research assistants and psychologists with experience in counselling and conversation
196 techniques were responsible for the development of the guidelines and the implementation
197 and analysis of the interviews. They were also involved in the development of the manuals for
198 the patient and doctor-directed interventions. Apart from a short telephone contact to arrange
199 the interview date, the interviewers did not know the interviewees beforehand. They introduced
200 themselves as part of the study team responsible for evaluating the intervention. Participants
201 were informed that the study-doctor who conducted the telephone intervention would have no
202 access to recordings or transcripts of individual patient interviews, but only to aggregated, pre-
203 processed data of all the interviewees.

204 The interview dates were scheduled about 3 months after the telephone intervention. For
205 practical reasons, this period between the intervention and the interview varied between 2.5
206 and 6.5 months (on average 3.5 months) among the patients. For the doctors, the time period
207 varied between 2.5 and 7.3 months (on average 3.8 months). All interviews were digitally
208 audio-taped in full. No field notes were taken during the interview. The audio recordings were
209 transcribed verbatim by an external transcription service provider. Personal data were
210 pseudonymised before data analysis. Neither transcripts nor results were returned to
211 participants for feedback.

212

213 **Data analysis**

214 The transcripts of the interviews were analysed using qualitative content analysis largely based
215 on the approach of Kuckartz (2018)[17], which involves both deductive and inductive coding.
216 The chosen multi-level procedure for this study is outlined in Table 2.

217

218 Table 2 *Levels of the qualitative content analysis*

Familiarisation stage	Before coding, the entire transcribed text material was read intensively in the process of pseudonymisation and short case summaries were composed.
Inductive-deductive development of the initial coding frame	Based on this familiarisation stage, codes were extracted inductively by N.A. In a next step, additional codes were derived deductively from key topics of the interview guideline, from previous research on barriers that influence patients' adherence to preventative measures [18] and from the underlying theoretical HAPA.
Quota sample trial phase and revision	This initial coding frame was then applied to a quota sample consisting of 20% of the data material (N=5 patient and N=2 doctor interview transcripts), comprising interviews from both interviewers collected at various time points during data collection. In the process of this trial phase, the codes were refined several times through continuous reflection and classified into main and sub-codes.
Entire data material trial phase and team-review	This was followed by the first coding of the entire data material along the so far defined coding frame. In this process, codes were again revised if required, e.g. summarised or differentiated into further sub-codes. In this process a coding guideline was formulated. To ensure intersubjective comprehensibility, the coding frame, the guideline and the coding of individual, randomly chosen interviews were critically reviewed by M.B., M.G. and E.F. and, if needed, slightly adapted to their feedback. This resulted in the final set of six main codes and 11 sub-codes for patients and four main codes and four sub-codes for doctors (for an overview see table 3 and 4).
Application of the final coding system	This final coding system was then applied to the entire data material by N.A.
Extraction of a code x participant-summary-matrix	In the last step, all the statements of a participant assigned to the same code were paraphrased and the overall findings were extracted from a code x participant-summary-matrix.

219

220 Data organisation and analysis was performed using MAXQDA Plus 2020 (version 20.0.3)
 221 qualitative data analysis software. Following quantitative descriptive information was
 222 calculated using IBM SPSS Statistics (version 27). The entire patient data material to be
 223 analysed had covered a duration of about 712 minutes, the data material of doctors circa 148
 224 minutes. The patient interviews lasted between 9 and 75 minutes, with an average length of

225 28 minutes; doctor interviews lasted between 7 and 30 minutes, on average 18 minutes. The
 226 interviews were conducted in German. Code descriptions and quotations taken from the
 227 interview transcripts given below are translations from German into English.

228

229 Table 3 *Final coding system of patients' interviews*

Main codes	Sub-codes
Implementation of preventative measures	
Barriers to implementation of preventative measures	
Perceptions of the intervention	<i>Evaluation of the telephone intervention and accompanying information material</i>
	<i>Personal relevance of the intervention</i>
Perceived impact and usefulness of the intervention for implementation	<i>Implementation of preventative measures</i>
	<i>Motivation for implementation</i>
	<i>Initiation and maintenance of steps necessary for implementation</i>
	<i>Initiation and maintenance of implementation through prior planning</i>
	<i>Perceived effects of the intervention on the GP</i>
Infection-related risk perception following the intervention	<i>Cognitive-affective level</i>
	<i>Behavioural level</i>
Barriers and helpful factors for implementation of preventative measures following the intervention	<i>Barriers to implementation</i>
	<i>Helpful factors: social support</i>

230

231 Table 4 *Final coding system of doctors' interviews*

Main codes	Sub-codes
Barriers to implementation of preventative measures	<i>Evaluation of the telephone intervention and accompanying information material</i>
Perceptions of the intervention	<i>Relevance of the intervention for own professional work</i>
Perceived impact and usefulness of the intervention for implementation	<i>Implementation of preventative measures</i>
	<i>Perceived impact on further medical action</i>
Barriers to implementation of preventative measures following the intervention	

232

233 FINDINGS

234 **Patients' interviews**

235 Implementation of preventative measures

236 Only few patients made reference to prevention measures that had been implemented prior to
 237 study participation, with most of them indicating initial approaches and none the full
 238 implementation of recommendations. Patients reported having already received (some or all
 239 of) the recommended initial vaccinations. These vaccinations had been administered post-
 240 splenectomy by the hospital conducting the splenectomy, after discharge by the GP, a
 241 specialist or during rehab and, in two cases of elective surgery, even before the splenectomy.
 242 Furthermore, a few patients stated that they had already received a medical alert card for
 243 asplenic patients from hospital, which, however in some cases were not filled out completely
 244 or not permanently available.

1
2
3 245 Barriers to implementation of preventative measures

4
5 246 Regarding barriers to implement preventative measures, personal, contextual, as well as
6
7 247 doctor-attributed factors could be found. The majority of patients mentioned their own
8
9 248 insufficient or complete lack of knowledge about the infection risk associated with asplenia and
10
11 249 (the need for) corresponding preventative measures. Poor relevant knowledge and failures in
12
13 250 implementation were largely attributed to the GP, to the hospital or the rehab centre (or their
14
15 251 cooperation), with patients stating that they were either inadequately, incorrectly,
16
17 252 incomprehensibly or not at all educated and patients assumed that a lack of relevant
18
19 253 knowledge, time or priority by the health care providers were the reasons.

20
21
22
23 254 *'However, the hospital staff said that everything was okay and that it was possible to live*
24
25 255 *without a spleen.'* [ID020314]

26
27
28 256 Furthermore, comorbidity (mostly cancer) and/or the poor health condition of patients
29
30 257 influenced measure implementation as disease-related fears and treatments gave less priority
31
32 258 to vaccinations necessitated by the splenectomy or were the reason for their temporary
33
34 259 contraindication. Contextual barriers included vaccine supply difficulties and vaccine costs
35
36 260 considered not being borne by the health insurance. The results presented below refer to the
37
38 261 intervention and to experiences following the intervention.

39
40
41
42 262 Perceptions of the intervention

43
44 263 *Evaluation of the telephone intervention and accompanying information material*

45
46 264 As regards the evaluation of the telephone intervention, a relatively homogeneous picture
47
48 265 emerged. Respondents experienced it as pleasant, patient-centred and some mentioned they
49
50 266 felt taken care of. The information provided was evaluated as being informative and
51
52 267 comprehensible (except for some of the technical terms and abbreviations used). Duration was
53
54 268 deemed appropriate and necessary. As to the information material, patients stated they made
55
56 269 use of it and some kept it to be able to refer to it at any time. It was rated as informative (in
57
58 270 particular the vaccination schedule included) and comprehensible. However, some people
59
60 271 clearly expressed the added value of the telephone intervention aligned to the written

1
2
3 272 information material over only having the information material, especially when considering
4
5 273 comprehension.

6
7
8 274 *Personal relevance of the intervention*

9
10 275 Beyond the evaluation of the intervention, its personal relevancy for the participating patients
11
12 276 became apparent. Interviewees were appreciative of having received previously unknown or
13
14 277 incomplete disease-specific information they rated as subjectively important. They stated that
15
16 278 their awareness of risk factors and necessary prevention was formed or increased by the (new)
17
18 279 information and some reported they felt safer having been educated now.

19
20
21 280 *'And I have to say, it has also given me a sense of security. And the education was very good,*
22
23 281 *because, as I said before, I had no idea [...]' [021310]*

24
25
26
27 282 Impact and usefulness of the intervention for implementation

28
29 283 *Implementation of preventative measures*

30
31 284 All the respondents who provided information on immunisation had received the recommended
32
33 285 vaccinations since the telephone intervention or had already planned outstanding (or booster)
34
35 286 vaccinations. The medical alert card and the antibiotics for emergency treatment were also
36
37 287 mostly permanently available to patients (left in the car, handbag, wallet or mobile phone case),
38
39 288 even though there were some failures in filling the alert card in.

40
41
42
43 289 *Motivation for implementation*

44
45 290 Some participants explicitly expressed that the intervention had nudged them to plan,
46
47 291 implement or adhere to preventative measures or to demand implementation from their GP.

48
49 292 *'[...] that the thought process started for me, what do I have to pay attention to for myself?*

50
51 293 *What do I need to make my general practitioner aware of?' [ID090709]*

52
53
54 294 Aside from that, three interviewees made reference to the influenza vaccination, which they
55
56 295 had never received before, but were convinced of its necessity due to the telephone
57
58 296 consultation.

1
2
3 297 *Initiation and maintenance of steps necessary for implementation*

4
5 298 A large proportion of patients said that they had seen their GP following the telephone
6
7 299 intervention to inform him or her of their participation in the study, of required preventative
8
9 300 measures and to demand their implementation. Among other things, patients themselves (co-
10
11 301)monitored and organised vaccine supply, vaccination dates and sequence and some partially
12
13 302 filled in the medical alert card. In order to keep track of vaccination boosters and expiration
14
15 303 dates of the antibiotics, some reported making use of calendar reminders or other notes.

16
17
18 304 *Initiation and maintenance of implementation through prior planning*

19
20 305 Some interviewees stated that they followed the individual action plan they had established
21
22 306 during the telephone intervention prompted by the study doctor and that they made use of the
23
24 307 corresponding worksheet to monitor implemented and pending preventative measures.

25
26
27 308 *Perceived effects of the intervention on the GP*

28
29 309 During a consultation following the telephone intervention, patients reported that they
30
31 310 perceived their GPs being open to the (new) information and to study (participation).
32
33 311 Preventative measures would have taken an unprecedented priority as most doctors supported
34
35 312 the implementation by initiating or monitoring the process (e.g. deposited study information,
36
37 313 arranged vaccine supplies, reminders about (booster) vaccinations, or completion of the
38
39 314 medical alert card).

40
41
42
43 315 *'So, I have the impression that he's already got this properly on the agenda, to pursue it now*
44
45 316 *and also to take it further. [...]. And I attribute this to the conversation with you.'* [ID090709]

46
47
48 317 It has to be mentioned here, that, to the patient's knowledge, some of the GPs had received
49
50 318 the telephone intervention for doctors at the time of the patient interview and others had not
51
52 319 (yet).

1
2
3 320 Infection-related risk perception following the intervention

4
5 321 *Cognitive-affective level*

6
7 322 Some patients indicated that they had (initially) been alarmed, concerned or anxious when
8
9 323 receiving (largely) unfamiliar information on the asplenia-related infection and sepsis risk
10
11 324 through the intervention. Some described being uncertain about potential risk factors and signs
12
13 325 of sepsis as well as about whether they, in case of infection, would react properly. There were
14
15 326 also patients who were quite optimistic and unconcerned. Some of these (as well as some of
16
17 327 those who stated they were initially concerned) said that they felt safe and prepared to deal
18
19 328 with the existing risk thanks to comprehensive education, as well as through preventative
20
21 329 measures (to be) taken and knowledge of their efficacy.

22
23
24
25 330 *'Because before that, it was rather in abeyance. I just read and heard: Yes, blood poisoning,*
26
27 331 *far, far greater risk. [...]. However, after that [telephone intervention] it was a bit better [...]. So,*
28
29 332 *I don't imagine now my hand suddenly falling off from one second to the next.'* [ID021012]

30
31
32 333 *Behavioural level*

33
34 334 Besides the cognitive and affective consequences of risk perception, respondents also
35
36 335 adapted their behaviour following the intervention. Beyond implementation of the main
37
38 336 preventative measures, patients showed precautionary behaviour (i.e. avoiding crowds,
39
40 337 keeping their distance from potentially sick people, wearing face masks, being careful about
41
42 338 hand-hygiene, avoiding injuries and if needed seeing a doctor sooner) or were alert for
43
44 339 symptoms. Some interviewees made direct reference to the current COVID-19-pandemic,
45
46 340 which probably had enhanced or induced caution.

47
48
49 341 *'I'm also paying more attention to myself now, even more. And I check every day, is there*
50
51 342 *anything that doesn't belong there? This line or am I warm and have high temperature, [...].'*
52
53 343 [ID120714]

1
2
3 344 Barriers and helpful factors for implementation following the intervention
4

5 345 *Barriers to implementation*
6

7 346 For implementation of the targeted preventative measures following the intervention, again
8
9 347 personal, contextual as well as doctor-attributed barriers were depicted. The most common
10
11 348 personal reason for delayed or prolonged implementation of (booster) inoculations was
12
13 349 comorbidity (ongoing chemotherapy or immune treatment), less often mentioned was the
14
15 350 personal refusal of the influenza vaccination. Doctor-attributed barriers were poor support in
16
17 351 initiating and administering vaccinations, inadequate education about side effects by or
18
19 352 confusion about the vaccination sequence. Other barriers were vaccine supply shortages,
20
21 353 difficulties in appointment availability and coordination and, in one case, vaccination costs that
22
23 354 were assumed to not be covered by the health insurance. Concerning the medical alert card,
24
25 355 a few interviewees stated that they were not able to complete it themselves, with some GPs
26
27 356 refusing to help. One patient expressed discomfort at having to manage and carry several
28
29 357 (vaccination attesting) documents.
30
31

32
33 358 *'What I found a pity was that I often presented the medical alert card to my doctor, to my family*
34
35 359 *doctor, but they didn't want it at all... in fact, they didn't even look at it.'* [ID041710]
36
37

38 360 Reasons for not having antibiotics available for emergency treatment were lacking (patient or
39
40 361 doctor) conviction or knowledge of individual need, as well as lack of cooperation of the GP.
41
42 362 In another case, a patient criticised that her GP did not educate her about the use (including
43
44 363 dosage) of the prescribed antibiotic.
45
46

47 364 *Helpful factors: social support*
48

49 365 A good relationship, experienced general support, as well as professional advice and care by
50
51 366 the GP (and the GP co-workers) were mentioned as a helpful factor in prevention
52
53 367 implementation and in coping with their condition by many interviewees. Among other things,
54
55 368 it seemed to be of great significance for patients to be able to rely on their GP for (prospective)
56
57 369 measure implementation. A large proportion also felt supported emotionally and in prevention
58
59 370 implementation by their relatives (thanks to accompaniment to doctor's appointments, for
60

1
2
3 371 example). Some subjects actively involved family members (in one case also colleagues) by
4
5 372 informing them about the disease specifics and preventative measures necessary or already
6
7 373 taken (e.g. depository of emergency antibiotic supply).
8
9

10
11 374 Doctors' views
12
13

14
15 375 Barriers to implementation of preventative measures
16

17 376 For implementation of the preventative measures prior to study participation, interviewed
18
19 377 doctors mentioned both doctor (i.e. own) and health care system-related barriers as well as
20
21 378 patient-attributed barriers. Most notably, interviewees described own knowledge gaps or
22
23 379 uncertainties when it comes to asplenia-specific risks, updated vaccination recommendations
24
25 380 or the necessity of an antibiotic prophylaxis and some made reference to their minimal routine
26
27 381 in the treatment of this patient group. Furthermore, two doctors described deficits at the
28
29 382 hospital-outpatient care interface, on the part of the hospital (e.g. misleading information in the
30
31 383 discharge letter, lack of raising patients awareness of further out-patient care by GP) as well
32
33 384 as the own lack of awareness and assumed patient's failures.
34
35

36
37 385 *'And that is my mistake, the patient's mistake, and at the same time the [name of hospital]'s*
38
39 386 *mistake is also present, a hundred percent. All the stops have not been pulled out properly.'*
40
41 387 *[ID072212]*
42
43

44
45 388 Perceptions of the intervention
46

47 389 *Evaluation of the telephone intervention and accompanying information material*
48

49 390 The intervention was overall positively evaluated by all the GPs interviewed. The telephone
50
51 391 based intervention was viewed as pleasant, instructive and individually-adapted to prior
52
53 392 knowledge and the attending patient. The duration of the phone call was viewed as
54
55 393 appropriate. Accompanying information material was mostly used and/or deposited for future
56
57 394 recourse, content was evaluated as helpful and the scope (with one exception) as adequate.
58
59 395 Still, all the GPs gave preference to the telephone consulting over only written information
60
396 material (in terms of raising awareness and the opportunity to discuss aspects in depth).

1
2
3 397 *Relevance of the intervention for own professional work*

4
5 398 Beyond formal evaluation, the GPs addressed the effect of the intervention for their work. They
6
7 399 stated that they received subjectively new or up-dated information on asplenic preventative
8
9 400 care, classified as reliable (expert knowledge) and helpful for the treatment of their patients.
10
11 401 Besides knowledge (-reactivation), they mentioned increased attention to their (further)
12
13 402 patients affected and their own responsibility in implementing and monitoring (e.g. when it
14
15 403 comes to booster vaccinations, periodic renewal of antibiotic prescriptions) the precautions.

16
17
18 404 *'So we already knew what we had to do in case of asplenia, but we still hadn't had it on our*
19
20 405 *minds that much.'* [ID042812]

21
22
23
24 406 Impact and usefulness of the intervention for implementation

25
26 407 *Implementation of preventative measures*

27
28 408 GPs mentioned preventative measures already implemented or ongoing, mostly in terms of
29
30 409 vaccinations. Since the systematic record of their factual implementation was not the aim of
31
32 410 this interviews, but rather the experience of it, corresponding responses remained quite vague
33
34 411 and rare.

35
36
37 412 *Perceived impact on further medical action*

38
39 413 Besides implementation of the measures themselves, GPs also named heterogeneous other
40
41 414 consequences for their work. For instance, adaption of vaccination schedules and templates
42
43 415 for doctor's letters, storing of patients' asplenia-specific information in the internal system,
44
45 416 targeted summoning and broader education of affected patients as well as a more extensive
46
47 417 diagnostic work-up in the case of infections.

48
49
50
51 418 Barriers to implementation of preventative measures following the intervention

52
53 419 As regards the implementation of the preventative measures following the intervention, doctors
54
55 420 (i.e. own), health care system-related and patient-attributed barriers as well as contextual
56
57 421 factors were described by interviewed GPs. Doctor-attributed barriers to vaccination were lack
58
59 422 of clarity in the case of concurrent other treatment (e.g. chemotherapy) and inconsistencies in

1
2
3 423 the vaccination sequence originating from the hospital. At the patient level, comorbid diseases
4
5 424 and poor health as well as associated uncertainties posed an obstacle (e.g. refusing
6
7 425 immunisation during chemotherapy out of fear). Furthermore, GPs stated vaccination delays
8
9 426 due to delivery constraints and named an extra effort of parallel vaccination documentation
10
11 427 (medical alert card for asplenia and vaccination certificate).
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

428 DISCUSSION

429 This study explored asplenic patients' and GPs' perceptions of a novel intervention aiming to
430 increase adherence to PSS prevention measures and their experiences in implementation
431 following this intervention by means of a process evaluation. The results of both participant
432 groups provide a relatively homogenous picture and will be discussed conjointly in the
433 following.

434 The intervention was overall positively evaluated by both patients and GPs. This referred to
435 the intervention framework, comprehensiveness and informative value as well as to its
436 recipient-centeredness, with the telephone based part of the intervention outweighing the
437 written information material provided. Furthermore, the intervention seemed to have a great
438 personal relevance for patients and for the attending doctors' professional work. Both groups
439 reported newly emerged or increased subjective relevant knowledge. This was linked to a
440 sense of security of being well informed in one's own matter on the part of the patients while
441 GPs mentioned an increased sense of responsibility in the implementation of precautions and
442 several practical implications in the asplenic patients' management.

443 Even though barriers to initial adherence were not an intended focus of the interviews, most
444 participants referred to it. Both similarities and deviations from relevant studies could be found.
445 Corresponding to previously reported studies, poor relevant patient knowledge were found[4,
446 5, 7]. Furthermore, comorbid diseases influenced feasibility of the measures, as well as deficits
447 in inter-sectorial communication, the latter also being identified as a key barrier for doctor
448 guideline-conform patient management[4]. However, in comparison to DiSabatino et al.
449 (2017)[8], who described asplenic patients' concerns about the safety of vaccination or
450 scepticism about its benefits as barriers to vaccine prophylaxis, these aspects were not
451 detectable in our interviews.

452 The intervention, which was theoretically based on the HAPA[12], seemed to be an appropriate
453 strategy to promote asplenic patients' intention to action, action planning and subsequently, to
454 improve adherence to prevention measures. Patients portended they developed risk
455 awareness, were convinced, and felt motivated and empowered to plan and implement

1
2
3 456 preventative measures or demand their initiation from their GPs. It can be suggested that
4
5 457 patients demonstrated self-management behaviour, they presumably did not show before.
6
7 458 Risk awareness was manifested on the cognitive-affective level with a tendency of increased
8
9 459 anxiousness and mental preoccupation or realistic risk estimation and self-efficacy, as well as
10
11 460 in increased health precautionary behaviour and alertness for infection symptoms. Overall, the
12
13 461 results indicate that the targeted prevention measures were mostly implemented appropriately
14
15 462 and in full following the intervention. Subject to the pending quantitative evaluation, we thus
16
17 463 have initial indications that our findings fit in with other research showing the feasibility of
18
19 464 HAPA-based interventions in the context of prevention behaviour[i.a. 13].

20
21
22 465 Our results depict helpful factors and barriers to implementation. As far as helpful factors are
23
24 466 concerned, patients alluded to the social support of their GPs, as well as through relatives.
25
26 467 Patient and GP reported barriers can be divided into patient-attributed, doctor and contextual
27
28 468 or health care system-related factors. Reasons for prolonged or missed vaccination were
29
30 469 comorbidities and related treatments (e.g. chemotherapy) and, very rarely addressed, a
31
32 470 patient's personal refusal. Lack of knowledge, support and education on the part of the GPs
33
34 471 were also negatively contributing factors. Other reasons were at a contextual level, e.g. vaccine
35
36 472 supply constraints, lack of appointment availability or, brought in by GPs, cooperation deficits
37
38 473 between hospital and out-patient care. Since the intervention aimed to address evidenced
39
40 474 barriers, it corresponds with the expectation that in the overall picture, these were disease-
41
42 475 related or structurally given barriers, which could not be addressed by the intervention (e.g.
43
44 476 vaccine availability), that would emerge.

45
46
47 477 The interpretation of all the results must be done bearing in mind that selection bias cannot be
48
49 478 ruled out. As participation in the interviews was a voluntary additional effort, participating
50
51 479 patients and GPs might be a certain subgroup of study participants who tend to be motivated
52
53 480 or in favour of the intervention and thus may have induced a positive bias in terms of
54
55 481 intervention evaluation and reported implementation. Furthermore, selection might have
56
57 482 influenced patient-reported barriers (e.g. mostly action-related, rather than personal attitudes
58
59 483 opposing prevention measures). Although the patient selection was purposefully aiming at

1
2
3 484 maximum variation regarding their pre-interventional adherence ('PrePSS-score'), it must be
4
5 485 further mentioned that very high levels of the PrePSS-score did not occur at all in the sample.
6
7 486 However, we argue that this is less severe, as it represents exactly those patients who are the
8
9 487 target group of our intervention, as the intervention is not urgent for patients with high
10
11 488 adherence scores. Beyond that, it should generally be noted that the prompting of certain
12
13 489 issues during the guideline-based interview might have narrowed or limited the answers given.
14
15 490 In conclusion, our findings reveal a positive evaluation and a patient and GP perceived benefit
16
17 491 of the theory-based intervention, thus fulfilling one requirement for a successful implementation
18
19 492 of the intervention. In a next step, the quantitative evaluation of the intervention will be
20
21 493 conducted and recommendations for implementation in usual care will be made on the basis
22
23 494 of the overall evaluation.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 496 **DECLARATIONS**

4
5
6 497 **Funding**

7
8 498 This work was supported by *Innovationsausschuss of Gemeinsamer Bundesausschuss*,
9
10 499 Wegelystraße 8, 10623 Berlin, info@if.g-ba.de (grant number: 01VSF17049). The funding
11
12 500 body was not involved in any aspect of the design of the study, collection of study data, in
13
14 501 writing the manuscript, or in the decision to submit this article for publication.

15
16
17 502 **Competing interests**

18
19 503 None declared.

20
21
22 504 **Author contributions**

23
24 505 Study conception: MG, EF, SR. Development of interview guideline and coding system: NA.
25
26 506 Critical review of the interview guideline and coding system: MB, MG, EF. Data collection and
27
28 507 analysis: NA, MB. Data interpretation: NA, MB, MG, EF. Drafting and revision of the
29
30 508 manuscript: NA. All authors read, contributed to and approved the final manuscript.

31
32
33 509 **Patient consent for publication**

34
35 510 Not required. This manuscript does not contain any patients' individual medical information.

36
37
38 511 **Data sharing**

39
40 512 Not applicable.

41
42
43 513 **Ethical approval**

44
45 514 The study was approved by the Ethics Committee of the Albert-Ludwigs-University Freiburg
46
47 515 (No. 380/18, vote from 22 of November, 2018). Informed consent of each patient is obtained
48
49 516 in writing prior to participation.

50
51
52 517 **Acknowledgements**

53
54 518 We would like to thank Dr. Christian Schlett for peer review and comprehensive feedback on
55
56 519 the manuscript. We would also like to thank Rebekka Allen for language editing. Furthermore,
57
58 520 we would like to acknowledge that part of this work has previously been presented at the 20th

1
2
3 521 German Conference for Health Services Research: Anka N, Bayrhuber M, Rieg S, et al.
4
5 522 Akzeptanz und Umsetzung einer Intervention zur Infektionsprävention bei Patient*innen ohne
6
7 523 Milz (Asplenie) - Ergebnisse einer qualitativen Interviewstudie [Acceptance and
8
9 524 implementation of an infection prevention intervention in patients without spleen (asplenia) -
10
11 525 results of a qualitative interview study]. *20th German Conference for Health Services.*
12
13 526 Düsseldorf: German Medical Science GMS Publishing House 2021 Doc21dkvf204
14
15 527 (21dkvf204)].
16
17

18
19 **528 Exclusive Licence**

20
21 529 I, the Submitting Author has the right to grant and does grant on behalf of all authors of the
22
23 530 Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive
24
25 531 licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has
26
27 532 agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US
28
29 533 Federal Government officers or employees acting as part of their official duties; on a worldwide,
30
31 534 perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees
32
33 535 and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish
34
35 536 the Work in BMJ Open and any other BMJ products and to exploit all rights, as set out in our
36
37 537 licence.
38

39
40 538
41
42 539 The Submitting Author accepts and understands that any supply made under these terms is
43
44 540 made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your
45
46 541 employer or a postgraduate student of an affiliated institution which is paying any applicable
47
48 542 article publishing charge ("APC") for Open Access articles. Where the Submitting Author
49
50 543 wishes to make the Work available on an Open Access basis (and intends to pay the relevant
51
52 544 APC), the terms of reuse of such Open Access shall be governed by a Creative Commons
53
54 545 licence – details of these licences and which Creative Commons licence will apply to this Work
55
56 546 are set out in our licence referred to above.
57
58
59
60

547 REFERENCES

- 548 (1) Bianchi FP, Stefanizzi P, Spinelli G, et al. Immunization coverage among asplenic
549 patients and strategies to increase vaccination compliance: a systematic review and
550 meta-analysis. *Expert Rev Vaccines*2021;20:297-308
551 doi:10.1080/14760584.2021.1886085 [published Online First: 14 February 2021].
552
- 553 (2) Theilacker C, Ludewig K, Serr A, et al. Overwhelming postsplenectomy infection: a
554 prospective multicenter cohort study. *Clin Infect Dis*2016;62:871-8
555 doi:10.1093/cid/civ1195 [published Online First: 23 December 2015].
556
- 557 (3) Davies JM, Lewis MP, Wimperis J, et al. Review of guidelines for the prevention and
558 treatment of infection in patients with an absent or dysfunctional spleen: prepared on
559 behalf of the British Committee for Standards in Haematology by a working party of
560 the Haemato-Oncology task force. *Br J Haematol*2011;155:308-317
561 doi:10.1111/j.1365-2141.2011.08843.x.
562
- 563 (4) Lammers AJ, Hoekstra JB, Speelman P, et al. Doctors report barriers to deliver best
564 practice care for asplenic patients: a cross-sectional survey. *PLoS*
565 *One*2011;6:e17302 doi:10.1371/journal.pone.0017302.
566
- 567 (5) El-Alfy MS, El-Sayed MH. Overwhelming postsplenectomy infection: is quality of
568 patient knowledge enough for prevention? *Hematol J*2004;5:77-80
569 doi:10.1038/sj.thj.6200328.
570
- 571 (6) Kealey GP, Dhunge V, Wideroff MJ, et al. Patient education and recall regarding
572 postsplenectomy immunizations. *J Surg Res*2015;199:580-585
573 doi:10.1016/j.jss.2015.05.063 [published Online First: 11 June 2015].
574
- 575 (7) Meerveld-Eggink A, de Weerd O, Rijkers GT, et al. Vaccination coverage and
576 awareness of infectious risks in patients with an absent or dysfunctional spleen in
577 the Netherlands. *Vaccine*2008;26:6975-6979 doi:10.1016/j.vaccine.2008.09.052.
578 [published Online First: 9 October 2008].
579
- 580 (8) Di Sabatino A, Lenti MV, Tinozzi FP, et al. Vaccination coverage and mortality after
581 splenectomy: results from an Italian single-centre study. *Intern Emerg*
582 *Med*2017;12:1139-1147 doi:10.1007/s11739-017-1730-9 [published Online First: 10
583 August 2017].

- 1
2
3 584
4 585 (9) Luu S, Spelman D, Woolley IJ. Post-splenectomy sepsis: preventative strategies,
5 586 challenges, and solutions. *Infect Drug Resist*2019;12:2839-2851
6 587 doi:10.2147/IDR.S179902.
7
8 588
9
10 589 (10) Coignard-Biehler H, Lanternier F, Hot A, et al. Adherence to preventative measures
11 590 after splenectomy in the hospital setting and in the community *J Infect Public*
12 591 *Health*2011;4:187-194 doi:10.1016/j.jiph.2011.06.004 [published Online First: 21
13 592 September 2011].
14 593
15 594 (11) Bayrhuber M, Anka N, Camp J, et al. Prevention of post-splenectomy sepsis in
16 595 patients with asplenia - a study protocol of a controlled trial. *BMC Infect*
17 596 *Dis*2020;20:1-11 doi:10.1186/s12879-019-4752-2.
18 597
19 598 (12) Schwarzer R, Lippke S, Luszczynska A. Mechanisms of health behavior change in
20 599 persons with chronic illness or disability: the Health Action Process Approach
21 600 (HAPA). *Rehabil Psychol*2011;56:161-170 doi:10.1037/a0024509.
22 601
23 602 (13) Zhang CQ, Zhang R, Chung PK, et al. Promoting influenza prevention for elderly
24 603 people in Hong Kong using health action process approach: study protocol. *BMC*
25 604 *Public Health*2018;18:1-9 doi:10.1186/s12889-018-6146-6.
26 605
27 606 (14) Skivington K, Matthews L, Simpson SA, et al. A new framework for developing and
28 607 evaluating complex interventions: update of Medical Research Council guidance.
29 608 *BMJ*2021;374:n2061 doi10.1136/bmj.n2061.
30 609
31 610 (15) Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research
32 611 (COREQ): a 32-item checklist for interviews and focus groups. *Int J Qual Health*
33 612 *Care*2007;19:349-357 doi:10.1093/intqhc/mzm04 [published Online First: 14
34 613 September 2007].
35 614
36 615 (16) Helfferich C. Die Qualität qualitativer Daten: Manual für die Durchführung
37 616 qualitativer Interviews (4. Aufl.). Wiesbaden: VS Verlag 2011:167-193
38 617 doi:10.1007/978-3-531-92076-4.
39 618
40 619 (17) Kuckartz U. Qualitative Inhaltsanalyse: Methoden, Praxis, Computerunterstützung.
41 620 Weinheim: Beltz Juventa 2018.
42 621

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

622 (18) Habersaat KB, Jackson C. Understanding vaccine acceptance and demand - and
623 ways to increase them. *Bundesgesundheitsblatt Gesundheitsforschung*
624 *Gesundheitsschutz*2020;63:32-39 doi:10.1007/s00103-019-03063-0.

For peer review only

Supplemental Material; ANKA et al.

Suppl. Table 1

Interview guideline of patient participants

Welcome and introduction

Introduction of interviewer, aim and procedure of the interview

Interview-questions (*obligatory core questions in bold*)

Evaluation of the telephone intervention (initial question)

Thinking back to the telephone training with the doctor, how did you find that conversation?

How did you feel about the conversation?

What do you remember positively/negatively?

How was the information?

Is there something that would have been helpful for you to know but which did not come up during the phone call? If so, what?

How did you feel about the duration of the phone call?

Experience in implementing the preventative measures

How was the implementation of the preventative measures in your daily life?

What went well? What was easy for you to implement?

Were there any difficulties in implementing some of the precautionary measures? Was anything cumbersome or difficult to implement?

[If yes,] how did that go? What helped you?

Did you discuss these steps with the doctor on the phone beforehand? How was that for you?

What are the next steps concerning the prevention measures?

Dealing with sepsis risk

You have also talked about the increased risk of sepsis with the doctor. How did that go?

Are you now more concerned about developing a sepsis? If yes, why?

Do you feel able to deal with the risk?

Supplementary block: Information material

How do you rate the information material that was sent to you by post?

Conclusion and acknowledgement

Do you want to address something we have not talked about yet?

Supplemental Material; ANKA et al.

Suppl. Table 2

Interview guideline of doctor participants

Welcome and introduction

Introduction of interviewer, aim and procedure of the interview

Interview-questions (*obligatory core questions in bold*)

Evaluation of the telephone intervention (initial question)

When you think back to the conversation with the doctor from the university hospital, how did you feel about it overall?

What did you like / less like? Do you have any specific improvement suggestions?

How (comprehensible) was the information? Which of the information did you find most (or least) helpful?

Is there something that would have been helpful for you to know, but which did not come up during the phone call? If so, what?

What did you think of receiving the information on the phone? Do you think the written information (without the phone call) would have been sufficient?

How did you feel about the duration of the phone call?

Usefulness of the intervention

Did the information influence your further treatment or education of the affected patient?

If so, how? What information specifically?

If not, for what reason?

Written information material

How do you rate the information material that was sent to you by post?

Online information

The information material included a web address for a website on asplenia. Did you use it and, if so, how?¹

Expert question

In your view, is there (anything else) that we could improve?

Conclusion and acknowledgement

Do you want to address something we have not talked about yet?

¹ During the telephone intervention, doctors were referred to an asplenia-website for further information. As this aspect is not relevant for the present work, no corresponding results are reported.

STUDY PROTOCOL

Open Access



Prevention of post-splenectomy sepsis in patients with asplenia - a study protocol of a controlled trial

Marianne Bayrhuber^{1†}, Natascha Anka^{1†}, Johannes Camp², Manuela Glattacker¹, Erik Farin¹ and Siegbert Rieg^{2*}

Abstract

Background: Patients with asplenia have a significantly increased lifelong risk of severe invasive infections, particular post-splenectomy sepsis (PSS). Clear preventive measures have been described in the literature, but previous studies found poor implementation of prevention recommendations. Aim of the study is to improve the adherence to guideline-based preventive measures and thereby reduce the incidence of PSS by a novel telephone-delivered intervention that involves both patients and their physicians.

Methods: A prospective controlled, two-armed historical control group design is used to evaluate the new intervention compared to usual care. The intervention for patients includes both educational aspects and, building on the Health Action Process Approach (HAPA), intervention components that promote motivation and planning of preventive measures. For physicians the intervention is primarily information-based. The primary outcome, the adherence to preventative measures, is indicated by a study-specific 'Preventing PSS-score' (PrePSS-score), which is assessed at baseline and at 6-months follow-up. Secondary outcomes include, amongst others, patient self-efficacy and action-planning, asplenia-specific health literacy, general self-management and asplenia-specific self-management. In a process-evaluating part of the study interview-data on patients' and physicians' evaluation of the intervention will be gathered.

Discussion: This trial will provide evidence about the effectiveness of the novel prevention intervention for asplenic patients. If demonstrated beneficial, the intervention manual will be made publicly available to enable implementation in practice. The experience gained within this trial may also be valuable for prevention strategies in patients with other diseases.

Trial registration: German Clinical Trials Register (DRKS): [DRKS00015238](https://www.drks.de/DRKS00015238); Trial registration date 07. December 2018.

Keywords: Asplenia, Post-splenectomy sepsis, Overwhelming post-splenectomy infection, Telephone intervention, Sepsis, Splenectomy, HAPA, Vaccination, Prevention

Background

The spleen is the largest lymphatic organ and plays a crucial role in linking innate and adaptive immunity. As a result, the absence of the spleen is associated with significant morbidity and mortality [1]. Patients with anatomical asplenia (partial or total surgical removal of the spleen) or functional asplenia (loss of function of the

spleen) have a significantly increased lifelong risk of severe invasive infections [2, 3]. The mortality of post-splenectomy sepsis (PSS, also called overwhelming post-splenectomy infection [OPSI]), the most dangerous complication, reaches 30–50% [4]. Studies report incidence rates of 7–8 infections requiring hospitalization per 100 patient-years and a post-splenectomy sepsis incidence of 1 per 100 patient-years. Compared to the general population, patients with asplenia have an approximately 6-fold increased risk of sepsis-related hospitalization [5].

The high mortality of these infections has led to guidelines for the prevention of sepsis in asplenic and

* Correspondence: siegbert.rieg@uniklinik-freiburg.de

Marianne Bayrhuber and Natascha Anka are first authors.

²Division of Infectious Diseases, Department of Medicine II, Medical Center – Faculty of Medicine, University of Freiburg, Freiburg, Germany
 Full list of author information is available at the end of the article



hyposplenic patients. These recommendations include patient education, vaccinations, prophylactic and stand-by antibiotics, medical alert cards, travel advice and early treatment of animal bites [6, 7]. Patients without a functioning spleen and their physicians should be educated about the everyday risk of overwhelming infections and the need of prompt recognition and treatment of infections.

Asplenic patients should receive sequential pneumococcal vaccination (13-valent conjugate followed by 23-valent polysaccharide vaccine), meningococcal vaccination (tetra-valent ACWY and serotype B vaccine), *Haemophilus influenzae* type b conjugate vaccine and yearly influenza vaccination. A stand-by antibiotic should be prescribed for emergency use ('pill in the pocket'). A smaller subgroup of patients (age < 5 years, patients after a PSS episode) should obtain antibiotic prophylaxis, although there is no international consensus on when to discontinue prophylaxis. Patients should carry a medical alert card that can inform physicians of the patient's asplenia, optimally. Furthermore, travellers to high-risk areas, for example with regard to malaria, should secure optimal preventive measures. The effectiveness of these prevention measures has been shown in several studies [8–10].

Nevertheless, despite from these clear recommendations, previous studies have found poor adherence to preventive measures [2, 11]. In a recent prospective multicenter cohort study from Germany [12], the vaccination status was queried in patients with PSS admitted to an intensive care unit. Only 21% of patients had been vaccinated in the past 5 years according to the recommendations for asplenic patients with a pneumococcal vaccine; only 6% had ever been vaccinated against meningococci and 12% against *H. influenzae*. Accordingly, only 12% of patients had received a seasonal influenza vaccination. In the asplenia registry study at the Medical Centre University of Freiburg, only 6% of patients treated as part of regular care by general practitioners had completed the vaccination schedule according to current recommendations [12]. The registry data also show impressively that the booster immunization rates for each vaccine are again significantly worse than the primary immunization rates. In addition, only a minority (47%) of patients had received prescriptions for stand-by antibiotics.

Reasons for the lack of adherence to recommended prevention measures could be, on the one hand, that the prevention measures are unknown to patients and physicians [8]. On the other hand, patients might not be aware of the increased risk of infections, which could explain the low adherence to preventive measures. Several studies suggest the 'Health Action Process Approach' (HAPA) as a theoretical framework for the understanding of health behaviour in general [13–15] and for

vaccination behaviour in particular [16–18]. The HAPA postulates a two-phase approach to action: Firstly, a pre-intentional motivational phase, which is characterized by risk perception, expectation of action results and expectation of self-efficacy and leads to an intention. And secondly, a post-intentional volition phase, which comprises factors as planning, action control, social support, recovery self-efficacy and leads to the actual health behaviour. Situational barriers and resources also play a role here as they influence the intention, planning and health behaviour. Social support, for example, represents a resource and the lack of it could be a barrier to adopt and maintain health behaviour [19]. Interventions to improve health behaviour beyond the passive provision of information material have not yet been described for asplenic patients.

Aim of the study is to improve the adherence to guideline-based preventive measures and thereby reduce the incidence of PSS by a novel telephone-based intervention that involves both patients and their general practitioners. By educating patients, the intervention contributes to the participation and empowerment of patients, who take responsibility for their own health in general and the implementation of prevention measures in particular. The new intervention is supposed to improve patients' health by reducing morbidity as well as mortality and increase the quality-of-life of patients with asplenia. In addition, it can be expected that the costs of health insurance companies will decrease, since the treatment and follow-up costs of post-splenectomy infections are relatively high compared to the planned intervention and implementation of preventive measures. Evidence for this assumption can be found in cost-effectiveness analyses of PSS prevention in asplenia registries [12, 20]. Furthermore, the development of such an intervention can serve as a model for other studies.

Our assumption is that a targeted intervention strategy increases the adherence to recommended prevention measures.

Methods/ design

Aims and hypotheses

The purpose of this study is to develop, manualize and evaluate a novel intervention that educates both patients and their physicians on appropriate preventive measures that should be undertaken to prevent infections after splenectomy. Besides information provision, the intervention is intended to motivate patients to implement the preventive measures and to convey action-related skills such as planning and managing barriers. It will be evaluated whether this targeted intervention (intervention group) is superior to usual care (historical control group) in terms of primary and secondary study outcomes. More precisely, we have put forward the

1
2
3
4 following hypotheses as to the outcome of the interven-
5 tion: (a) Adherence to infection-risk reducing preventive
6 measures will significantly be increased (primary out-
7 come). As a result, (b) the incidence of severe infections
8 associated with asplenia (particular PSS) and (c) related
9 health-care costs covered by health insurances will be
10 reduced (distal secondary outcomes). (d) Risk percep-
11 tion, intention to implementation, perceived self-efficacy,
12 action and coping-planning, positive and negative
13 outcome expectations and received social support
14 (HAPA-related variables) expected to account for the
15 effect of the intervention will significantly be enhanced
16 (proximal secondary outcomes). Furthermore, (e) disease
17 knowledge, patients' general and asplenia-specific self-
18 management, asplenia-specific health literacy, patient in-
19 volvement as well as health-related quality of life will
20 significantly be enhanced (distal secondary outcomes).

21 Beside this quantitative outcome-evaluation, interven-
22 tion patients' and intervention patients' physicians'
23 acceptance and evaluation of the intervention will be in-
24 quired in telephone interviews in a process-evaluating
25 part of the study.

27 Study design and setting

28 This intervention study is designed as a prospective
29 controlled, two-armed historical control group trial with
30 baseline, post- and follow-up measurement and process
31 evaluation (Fig. 1). The combination of outcome and
32 process evaluation meets the recommendations for
33 evaluating complex interventions [21]. As delaying the
34 delivery of information on preventive measures puts pa-
35 tients on a non-justifiable risk [8] we decided against a
36 randomized design and opted for a design with a histor-
37 ical control group for ethical reasons. In addition, the
38 historical control group optimally illustrates current
39 practice ('usual care').

40 The study is conducted by the Medical Center -
41 University of Freiburg, Germany (Division of Infectious
42 Diseases, Department of Medicine II and Section of
43 Health Care Research and Rehabilitation Research,
44 SEVERA) and the AOK Baden-Wuerttemberg, Germany.

46 Intervention

47 The intervention comprises a telephone-based individual
48 intervention session for patients with asplenia and a
49 separate intervention for their physician, conducted by
50 study physicians of the Medical Center - University of
51 Freiburg with expertise in clinical infectious diseases.
52 The content of the intervention was developed based on
53 comprehensive literature review, existing guidelines for
54 infection prevention and the study physicians' expert
55 knowledge. Both, the intervention sessions for patients
56 and for their physicians are manual-guided to ensure a
57 consistent practice across all study physicians; however,

the interview protocol is semi-structured to allow an in-
dividualized proceeding. When developing the manual,
particular attention was paid to its practical feasibility to
enable a future implication beyond this study.


Prior to the implementation of the intervention, all
participants are sent patient or physician tailored educa-
tional materials with brief information on the prophyl-
axis options along with a comprehensibly prepared
vaccination plan and a medical alert card for patients
with asplenia (see Additional file 1). It was developed by
the Medical Center - University of Freiburg, the
German Society of Infectious Diseases and the German
Sepsis Society.

46 Patient-directed intervention (intervention group)

The 20-min intervention session for patients in the
intervention group is divided into an information-giving
section and, following the HAPA theory, intervention
components that promote motivation for initiation (risk
perception, positive outcome expectancies and task self-
efficacy) and planning (action and coping planning,
maintenance self-efficacy) of recommended infection
prevention measures. Applied behavioral change tech-
niques according to Abraham and Michie [22] comprise:
providing information about behavior-health link and on
the benefits of preventive measures, providing instruc-
tion, prompting intention formation, specific goal setting
and barrier identification, assisting with relapse preven-
tion by teaching to use prompts or cues or plan social
support and use of follow-up prompts.

In the first section patients are provided with
evidence-based information on the immunological func-
tion of the spleen, on potential infections after the
spleen has been removed (targeting risk perception) and
are educated on the most important preventive measures
(targeting positive outcome expectancies). These com-
prise receiving asplenia-specific vaccinations (pneumo-
coccal, meningococcal and *Haemophilus influenzae* type
b) and annual influenza vaccinations. Moreover, patients
are advised to have an emergency supply of 'pill in the
pocket'-antibiotics to be taken in the event of sudden
illness. The medical alert card for asplenic patients that
informs health professionals about the splenectomy is
introduced to them.

In the motivational-section patients are informed
about the efficacy of the recommended preventive mea-
sures by means of a brief example on morbidity rates
found to be higher among asplenic patients who are pre-
sumably unaware of their increased infection risk than
among patients who received preventive education (tar-
geting risk perception and positive outcome expectan-
cies). Participants are sensitized to signs and symptoms
that may indicate infection and are educated about the
need of seeking rapid medical attention or taking



emergency stand-by antibiotics if residing far from medical care and symptoms of infection occur (targeting task self-efficacy). In doing so, the information is framed in a way as to increase the awareness of the patient's personal relevance rather than arousing fear of disease and it is focused on the feasibility of the recommended prevention behavior [23]. After explanation, patients are encouraged to determine which recommendations they want to follow by ticking corresponding boxes on their worksheets to prompt goal-setting.

In the planning-section patients are told that the aim is to facilitate implementation of the previously set prevention goals by precise planning. They are asked to

develop action plans defining when, where and how they would take the intended infection preventive measures, including necessary preparatory behaviors, e.g. making appointments, fill in the medical alert card by physician (targeting action planning). Beyond that, participants are prompted to anticipate potential personal barriers to implementation of their personal plans. Amongst others, they are encouraged to think of situations in which the medical alert card could presumably be forgotten or circumstances that may led them failing to complete a vaccination course. At the same time, patients are assisted to find ways to attain their goals despite the identified impediments, for instance by seeking support

1
2
3
4 from their networks (targeting maintenance self-efficacy
5 and coping planning). To promote transfer into partici-
6 pants' everyday lives they are encouraged to record their
7 individual action and coping plans on designated work-
8 sheets accompanying the session.

9 At the follow-up telephone call, all planned preventive
10 measures are assessed in order to calculate the PrePSS-
11 score and, when indicated, potential barriers to imple-
12 ment plans are discussed. If further assistance for imple-
13 mentation is assumed, participants are re-motivated and
14 assisted to manage difficulties. Follow-up consultation is
15 optional and individually tailored to the patients' needs
16 and not manual-based.

17 **Short version of the patient-directed intervention (historical 18 control group)**

19 Patients in the historical control group receive a short-
20 ened version of the patient-directed intervention. The
21 short version includes the information-giving section on
22 the functioning of the spleen and on health implications
23 of asplenia (targeting risk perception, outcome expect-
24 ancy and task self-efficacy) as well as the motivational-
25 section on the efficacy of the recommended precautions
26 and on strategies for risk situations (targeting positive
27 outcome expectancy and task self-efficacy) since it is
28 important for ethical reasons that the control group is
29 provided with the same precautionary information as the
30 intervention group. However, the planning-section is
31 absent from the control group's intervention as specific
32 action plans and potential barriers are not discussed due
33 to a lack of time resources. The intervention in the
34 control group is implemented only for ethical reasons
35 and is not an intervention variant to be evaluated. Data
36 collection relevant for the study has already been com-
37 pleted in this group at the time of intervention imple-
38 mentation, thus a confounding influence on the
39 outcome variables can be ruled out.

40 **Physician-directed intervention**

41 The physician-directed telephone intervention comprises
42 evidence-based information on the consequences of
43 asplenia and the increased infection risk associated with
44 high mortality rates. Physicians are educated about
45 preventive measures consistent with current post-
46 splenectomy guidelines including currently recom-
47 mended vaccination and revaccination on the basis of
48 given immunization schedules, indication of stand-by
49 antibiotics and antibiotic prophylaxis. Furthermore, the
50 intervention session includes an introduction in the
51 purpose and use of the medical alert card and the
52 necessity of patient education, particularly as to the
53 patient-initiated antibiotic use in case of febrile illness.
54 Physicians are advised to document any antibiotics in
55 use and record a vaccine plan (vaccination status, need

and interval for revaccination) specific to their patient
using provided fields on the medical alert card.

The objective of the intervention is to heighten
physicians' awareness and knowledge of available pre-
ventive measures to improve guideline-based post-
splenectomy care. Thereby the information-provision
component is the integral part of the physician's inter-
vention. However, in line with the patients' intervention,
the physicians' intervention also targets risk perception,
positive outcome expectancy and, subsequently, motiva-
tion to follow guideline recommendations.

The intervention sessions take approximately 10 min.
All participating physicians receive the intervention irre-
spective of the group allocation of their patients.

41 **Participants and recruitment**

42 Participants are patients with anatomic asplenia and
43 their physicians (general practitioners or specialists).
44 Eligible are German-speaking patients aged 18 years or
45 older, who are insured by the cooperating health insur-
46 ance AOK Baden-Wuerttemberg, which is Germany's
47 5th largest health insurance and insures more than 4
48 million people.

49 Patient participants are preselected to either the inter-
50 vention or control group based on the time interval
51 since they underwent splenectomy. Patients who are
52 recently splenectomized (at most 4 months) are allocated
53 to the intervention group. Potential intervention patients
54 are recruited about 6–8 weeks after splenectomy suc-
55 cessively by biweekly request from February 2019 for a
56 maximum period of 18 months. The historical control
57 group consists of patients who are splenectomized since
58 more than 6 months (at most 18 months). Thus, pre-
59 interventional baseline-data on primary and secondary
60 outcomes in the historical control group account for
routine care. Potential control group patients were
recruited at the start date of study implementation
(January 2019) and, to attain the planned sample size,
another cohort of patients was contacted half a year later
(June 2019).

Potential patient participants are identified via a
database search (search criteria: OPS-code 5–413
splenectomy, with all sub-codes 5–413.0 [partial
splenectomy] and 5–413.1 [total splenectomy]) for all
splenectomized patients within the predefined group-
specific time periods since splenectomy by the AOK-
Baden-Wuerttemberg. Patients who meet criteria re-
ceive recruitment letters from the health insurance.
Those who are interested in study participation re-
ceive detailed information on the procedure, the aims
and the legal conditions of the study from the Uni-
versity Medical Centre Freiburg. Participants are
asked to provide written informed consent and con-
tact information if they agree to take part.

To identify the corresponding physician, participating patients are asked to provide contact information on their general practitioner or other physician who mainly cares for their asplenia and sign an agreement releasing the physician from medical confidentiality obligation. Physicians whose patients consent to having their physicians included in the study are recruited by letters with information concerning the study. No exclusion criteria for physicians are applied. Both patient and physicians will receive a 30€ voucher for participation after study completion.

Sample size considerations

A priori calculation of the sample size of patient participants to compare the intervention group to the historical control group in the primary outcome was performed with the software 'Power and Precision'. Based on an assumed medium to large effect size of 0.40, a statistical power of 80% and a significance level of 5% (two-sided) the minimum required patient sample of $N = 100$ per group was calculated. Further sample size considerations take into account the actual number of splenectomized patients insured by the AOK. An explorative request showed that 360–400 patients undergo splenectomy a year, resulting in approximately 500 patients assumed to be available for recruitment in the planned inclusion period of 18 months. Based on studies with similar patients [24], we further estimated a proportion of 50% non-respondents for the intervention group and attrition rates of 40% of respondents, so we aim to recruit 500 potential intervention group patients for an expected analysis sample of $N = 178$ participants. As this exceeds the statistically required number of cases despite conservative estimations, sufficient cases will be available even after considering potential deceases in the course of the study.

Given that the inclusion period (18 months) is the same for the control group (although retrospectively), sample size considerations for this group are largely the same, with the exception of an assumed proportion of 60% non-respondents and a dropout rate of 50%, resulting in expected $N = 110$ control group cases for analysis. Correspondingly, the number of physician participants included in analysis will be $N = 178$ intervention patients' physicians and $N = 110$ control patients' physicians maximum, considering that some patients may have the same physician.

Outcome measures

Primary outcome

The primary outcome, the adherence to preventative measures, is indicated by a study-specific 'Preventing

PSS-score' (PrePSS-score), which includes the following parameters: (a) receipt of guideline-conform sequential pneumococcal vaccination and (b) guideline-conform meningococcal vaccinations, (c) prescription and availability of stand-by antibiotics for emergency treatment and (d) handing out of and carrying a medical alert card for asplenic patients. The selection of the included parameters was made by Infectious Diseases specialists of the University Medical Center Freiburg based on current guidelines and recommendations on PSS prevention [25, 26].

To weight these preselected parameters, an expert survey was conducted prior to the study asking a total of 16 international experts in the care of asplenic patients to rate the items according to their importance in infection prevention, of which nine experts provided feedback. Based on the calculated median of the given expert-ratings the scoring system was defined (see Table 1 for an overview, for exact score formation and operationalization see Additional files 2 and 3).

The score for each patient is estimated by the study physicians according to both the patient's and the physician's information gathered through telephone-interviewing. To validate the self-report data on the primary outcome, health insurance patient routine data aggregated by groups (vaccinations relevant to asplenia and prescribed antibiotics) will be included.

Secondary outcomes

In this article secondary patient outcomes are classified on a proximal-distal continuum of outcome measures [27]. HAPA-related variables (i.e. patient's risk perception, self-efficacy and action-planning) are considered as proximal secondary outcomes which are assumed to be more likely and directly affected by the intervention than distal outcomes and observable shortly after the intervention. More global, distal secondary outcomes, are assumed to be also influenced by proximal outcomes as well as external, non-treatment factors. These include disease knowledge (disease knowledge is also expected to be a confounder), patient general and asplenia-specific self-management as well as asplenia-specific

Table 1 Parameters and scoring system of the PrePSS-score

Parameter	Score
(1) Guideline-conform sequential pneumococcal vaccination	0–3
(2) Guideline-conform meningococcal vaccination	0–3
(3) Stand by-antibiotic prescribed and available ('pill in the pocket')	0–2
(4) Handing-over and carrying a medical alert card	0–2
Total PrePSS-score [Range]	0–10

health literacy, self-reported patient involvement and health-related quality of life.

Secondary outcomes for physician participants are their subjective improvement in knowledge and their satisfaction with the intervention.

Questionnaires

Patient-related secondary outcome measures, potentially confounding variables and the patients' evaluation of the telephone-intervention are assessed via self-administered paper-pencil questionnaires incorporating already validated instruments as well as asplenia-specific scales developed for the purpose of this study, which are described below.

- (1) **HAPA-related outcomes.** To gather key HAPA variables addressed in the intervention, perceived disease risk relevant to asplenia, patients' behavioral intention to implementation, perceived self-efficacy for implementation, action and coping planning, positive and negative outcome expectations and received social support are assessed. Items were developed on the basis of the general assessment rules for HAPA constructs provided by Schwarzer et al. [19] and slightly adapted to infection prevention behavior in asplenia. Responses are rated on a six-point scale ranging from *fully correct* (1) to *not correct at all* (6) (except the scale *risk perception*).

Six items measuring *behavioral intention* to obtain prevention refer, for instance, to "undertake preventive measures recommended after splenectomy" and "obtain vaccinations". *Perceived self-efficacy* is assessed by ten items asking participants to rate their level of confidence in their ability to implement and cope with preventive measures, such as "I can correctly interpret symptoms of a severe infection" or "I will renew my emergency antibiotics after the expiration date". *Prevention behavior planning* is assessed with six items, four items measuring action planning as the items address the where and how of the precautions (e.g. "what kind of vaccinations I will get done") and two items measuring coping planning asking for situations that could interfere with their plans (e.g. "what I can do if I forget my emergency antibiotics"). *Positive and negative outcome expectancies* after implementing the preventive measures are assessed with three items asking for pros, e.g. "I'm better protected from the flu" and three items asking for cons, e.g. "I could suffer from side effects of vaccinations". *Received social support* regarding prevention implementation is measured with the stem "People around me (e.g.

family, friends)..." followed by five items, for example "have encouraged me to take preventive measures recommended after splenectomy". For *risk perception*, the item stem "If I compare myself with other people (of my age and sex), then my risk, sometime in future..." is followed by the items "to fall ill with blood poisoning", "to fall ill with meningitis" and "to get pneumonia", which are rated by participants on a scale from *significantly increased* (1) to *considerably lower* (5).

- (2) **Self-management.** General self-management is assessed with the two subscales *Self-Monitoring and Insight* and *Skill and Technique Acquisition* from the German version of the Health Education Impact Questionnaire (heiQ) [28, 29], a widespread tool developed to assess proximal outcomes of patient self-management programs, covering eight independent dimensions. The scale *Self-Monitoring and Insight* (six items) captures individuals' ability to monitor their condition that leads to insight and appropriate actions to self-manage as well as individuals' acknowledgment of realistic disease-related limitations. The scale *Skill and Technique Acquisition* (four items) covers the subjective appraisal of knowledge-based skills and techniques that help manage disease-related symptoms and health problems. Items are scored on a 4-point response scale (1 = *strongly disagree* to 4 = *strongly agree*) and averaged for the two scales, with higher values indicating a higher subjective judgement of self-monitoring and skills respectively.

- (3) **Asplenia-specific self-management and asplenia-specific health literacy.** To capture disease-specific self-management components, five items related to asplenia were developed on the basis of the heiQ-scales *Self-Monitoring and Insight* (three items) as well as *Skill and Technique Acquisition* (two items), described above. One item each derived from the heiQ-scales *Health-Service Navigation* and *Social Integration and Support* were used to develop two further items as these aspects are additionally relevant for asplenia-specific self-management.

A total of six items capturing asplenia-specific health literacy were derived from the Health Literacy Questionnaire (HLQ) [30]. The HLQ covers nine health literacy domains that reflect an individual's competencies and experiences when attempting to understand, access and use health-information or when trying to engage with health-care practitioners or services, of which five were used as basis for the development of the disease-specific health-literacy items. The response format for all self-developed items is a 6-point scale

- ranging from *fully correct* (1) to *not correct at all* (6).
- (4) **Patient involvement.** Patient involvement is measured with the German version of the Perceived Involvement in Care Scales (PICS) [31, 32] a 14-item generic instrument that is designed to assess patients' perceptions of participation in treatment decision making as well as physicians' efforts to facilitate patient involvement. It covers three categories of patient-physician communication: *Doctor Facilitation of Patient Involvement*, *Level of Information Exchange* and *Patient Participation in Decision Making*. The response scale is a 4-point Likert scale ranging from 1 (*strongly disagree*) to 4 (*strongly agree*), where higher scores indicate higher perceived patient activity and endorsement.
- (5) **Health-related quality of life.** The 12-item Short-Form-Health-Survey (SF-12, short version of SF-36) is administered to assess self-reported health-related quality of life referring to the past 4 weeks [33]. The SF-12 is a generic instrument that yields a subjective mental and physical health status summary score derived from four health components respectively: Physical health comprises *general health*, *physical functioning*, *role limitations due to physical health problems* and *bodily pain*; subjective mental health comprises *vitality (energy/fatigue)*, *social functioning*, *role limitations due to emotional problems* and *mental health*. High scale values indicate better health.
- (6) **Subjective and objective disease knowledge.** Subjective disease knowledge held by patients is assessed using two items asking them to rate their level of knowledge about the consequences of splenectomy and potential preventive measures on a 5-point scale (1 = *very great knowledge* to 5 = *non-existent knowledge*). Four additional questions are administered to ascertain the objective degree of knowledge about asplenicism. The items refer to the functions of the spleen, consequences of splenectomy, recommended precautions and patients theoretically behavior in case of sudden septic symptoms (of which the latter is derived from Gundling et al. [33]).
- (7) **Compliance and influenza prevention behaviors.** Patients' compliance with general health-preserving measures is estimated using four items of the German version of the Questionnaire of Multiple Health Behavior (MHB-39) [34] that load highest onto the domain *Compliance* (i.e. having regular check-ups and prophylactic vaccinations made, complying with physicians and consulting a doctor when indicated). The MHB-39 assesses habitual health-related behaviors on a 5-point Likert scale (1 = *never* and 5 = *always*). In our questionnaire, the MHB-39 compliance-items are supplemented by three questions asking for patients influenza prevention behaviors (i.e., washing hands after return to home and before touching food, avoid touching eyes or mouth in public, avoid hand shaking during flu season) taken from Zhang et al. [16] and translated into German.
- (8) **Depression and anxiety.** Indicators of depression and anxiety in patient participants are measured using the German version of the Patient Health Questionnaire for Depression and Anxiety (PHQ-4) [35], a validated four-item ultra-brief screening instrument that consists of a 2-item *depression scale* (Patient-Health-Questionnaire, PHQ-2) [35, 36] asking for DSM-IV diagnostic core criteria symptoms (i.e. loss of interest, depressed mood) and a 2-item *anxiety-scale* (Generalized Anxiety Disorder Scale, GAD-2) [36] representing core symptoms of a generalized anxiety disorder (feeling nervous and anxious, difficulty to stop or control worrying). The stem question for all items is: "Over the last two weeks, how often have you been bothered by any of the following problems?". Answers are given on a 4-point Likert-type scale ranging from *not at all* (0) to *nearly every day* (3). Scale scores ≥ 3 indicate the presence of a depression or an anxiety disorder, respectively.
- (9) **Evaluation of the telephone-intervention.** Patients are asked to judge patient-centered criteria of the telephone-intervention using six items relating to the content (i.e. topic selection, comprehensibility, and usefulness), materials and interaction (atmosphere, opportunity to make own comments or pose questions). Items are rated on a school grading scale ranging from (1) *very good* to (6) *very poor*. Two further open questions inquire positive feedback and suggestions for improvement. Items were taken from Meng et al. [37] and slightly adapted to our intervention.

Procedure

The chosen outcomes for patients are measured prior to the intervention (baseline measurement, t0), directly after the intervention (t1) and after a 6-month follow-up period (t2).

At t0, patients in the intervention group are sent paper-pencil pseudonymized questionnaires on baseline proximal and distal secondary outcomes and socio-demographic information. Upon receipt of the filled questionnaires, telephone appointments are arranged with patients for a study physician interview. During telephone calls, a vaccination history, use and availability of stand-by antibiotics and the medical alert card are

1
2
3
4 taken to gather baseline data on the primary outcome,
5 the PrePSS-score, along with some other medical infor-
6 mation relating to the patients' asplenia (e.g. indication
7 for splenectomy, splenectomy date and previous epi-
8 sodes of infection or PSS requiring hospitalization).

9 After t0-data collection, the patient-directed
10 telephone-intervention is implemented. The intervention
11 of the corresponding physician is conducted at about the
12 same time; however, the order is determined by the ar-
13 rangement of the telephone appointments and not stan-
14 dardized. Secondary physician outcomes are gathered
15 after the physician-directed intervention. Historical con-
16 trol group patients and their physicians go through the
17 same procedure and patients receive t0-questionnaires
18 identical to intervention group patients, but only inter-
19 vention participants continue measurement after the
20 telephone intervention.

21 Following each patient telephone call, intervention pa-
22 tients complete post-intervention questionnaires on the
23 proximal secondary outcomes similar to baseline items
24 and evaluate the telephone-intervention (t1).

25 To test for six-month sustainability of the effects of
26 the intervention they receive follow-up questionnaires
27 on distal secondary outcomes identical to baseline
28 measurement (t2). After return of the follow-up ques-
29 tionnaires, intervention patients are contacted by study
30 physicians via telephone again to inquire the same set of
31 data on the primary outcome and (changes in) medical
32 data, such as the incidence of infections and PSS, gath-
33 ered at t0.

34 To ensure a valid data basis, patients' self-report data
35 on the primary outcome variable and on the medical in-
36 formation are confirmed with the corresponding phys-
37 ician both at t0 and (in the intervention group) at t2. In
38 case physicians are interviewed prior to their patients,
39 patients are made aware of any discrepancies between
40 their information and information their physicians pro-
41 vided when required.

42 43 **Qualitative interviews for process evaluation**

44 A total of 20 patients of the intervention group and 10
45 intervention patients' physicians (first patients or
46 physicians who agree to participate) are surveyed 5.5
47 months after telephone-intervention (shortly before t2-
48 measurement) in semi-structured 20- to 30-min
49 telephone-interviews by psychologists of the project
50 team. Patients are interviewed on their acceptance and
51 perception of the telephone-intervention and accom-
52 panying materials as well as on the feasibility (e.g.
53 experience in implementation, helpful factors and
54 barriers) of intervention contents. Physicians are asked
55 for their subjective evaluation of the intervention (e.g.
56 usefulness, improvement suggestions). Interviews will be
57 audio-recorded with the permission from participants.

58 59 **Data analysis**

Demographic characteristics of the study population and
effect sizes in the intervention group will be reported
descriptively. The main analysis tests the hypothesis that
the PrePSS-score at follow-up is higher (better adher-
ence to infection-risk reducing preventive measures) in
the intervention group than in the control group. Due to
the non-randomized design a propensity score adjust-
ment is performed to reduce potential bias that may be
caused by differences on covariates in the two groups
[38]. We will apply general linear models with propen-
sity score as a covariate. The same method will be used
for the analysis of secondary outcomes. Assuming miss-
ing data in the questionnaires, multiple imputation will
be considered for corresponding analyses. Additional
analyses will be conducted with structural equation
modeling technique to test a priori specified mediation
models of intervention effects.

A cost-effectiveness analysis of the intervention will be
conducted by analyzing the change-from-baseline scores
of the primary and the secondary outcomes in relation
to the costs of the intervention. To reveal the economic
efficiency of the intervention, routine data will be used
to determine standard treatment and follow-up costs as-
sociated with infections requiring hospitalization and
with PSS in asplenic patients to contrast them to the
intervention costs.

In the qualitative analyses, the audio files of the inter-
views will be transcribed by an external service provider
and the transcripts will be analyzed using a qualitative
content analysis.

60 **Discussion**

Poor implementation of the prevention recommenda-
tions for patients without a functioning spleen has been
demonstrated in several studies. Better adherence to pre-
ventive measures is urgently needed [2, 11]. However,
conclusive and effective new strategies to improve care
beyond the passive provision of information have not yet
been described for asplenic patients.

Strengths of the current study are the development
and evaluation of a theory-based dual intervention, i.e.
focusing on patients and their physicians. By educating
and training patients, the intervention contributes to the
empowerment of the patients. Quantitative data will
allow us to evaluate the effect of the intervention on pre-
vention measures such as vaccinations, prophylactic and
stand-by antibiotic use and patient-related outcomes.
Qualitative interviews will enable us to understand e.g.
barriers in preventive behaviour. Furthermore, the new
intervention can be improved on the basis of feedback
from asplenic patients and their physicians. Following
this evaluative process, the intervention-manual will be

made publicly available to enable future implementation in practice.

The study has some limitations, which are mainly based on our sampling strategy. First, our sample contains a self-selected group of patients from the co-operating health insurance (AOK Baden-Wuerttemberg). Secondly, it is not a randomized controlled trial, however, due to above outlined ethical reasons randomization is not justifiable. In order to reduce a potential bias that may be caused by differences in covariates in the intervention vs. historical control group, propensity score matching will be applied. Third, the primary outcome, the PrePSS-score was developed via expert-ratings, however, weighting of the four included items may still need further refinement and research.

All in all, we believe that the experience gained with this type of intervention will also be very valuable for prevention strategies in patients with other diseases. The intervention could be considered - after demonstrated effectiveness - in the context of other poorly implemented primary prevention measures or standard vaccinations, e.g. influenza and pneumococcal vaccination in patients over the age of 60 years.

Supplementary information

Supplementary information accompanies this paper at <https://doi.org/10.1186/s12879-019-4752-2>.

Additional file 1. Medical Alert Card Asplenia.

Additional file 2: Table S2. Results of the expert survey.

Additional file 3: Table S3. Operationalization of the PrePSS-score parameters after weighting of the parameters.

Abbreviations

GAD-2: Generalized Anxiety Disorder Scale; HAPA: Health Action Process Approach; heiQ: Health Education Impact Questionnaire; HLQ: Health Literacy Questionnaire; MHB-39: Questionnaire of Multiple Health Behavior; OPSI: Overwhelming post-splenectomy infection; PHQ-2: Patient-Health-Questionnaire; PHQ-4: Patient Health Questionnaire for Depression and Anxiety; PICS: Perceived Involvement in Care Scales; PrePSS-score: Preventing PSS-score; PSS: Post-splenectomy sepsis; SF-12: 12-item Short-Form-Health-Survey

Acknowledgements

We would like to thank Michaela Ruf, Sara Olawumi, Catriona Mary Hennelly and Marina Schorch (University Medical Center Freiburg) and Sarah Treffert, Nadja El-Kurd, Sabine Garst and Katrin Tomaschko (AOK Baden-Wuerttemberg) for assistance and valuable discussions in planning and developing the study.

Authors' contributions

Drafting and revision of the manuscript: NA, MB. Initiation, conception, design and coordination of the research project: SR, MG, EF. Development of the intervention and evaluation materials: MB, NA, MG, EF. Implementation of the intervention: SR, JC. All authors read and approved the final version of the manuscript.

Funding

The study is funded by *Innovationsausschuss* of the *Gemeinsamer Bundesausschuss*, Wegelystraße 8, 10623 Berlin (grant number: 01VSF17049). The funding body was not involved in any aspect of the design of the study,

collection of study data, in writing the manuscript, or in the decision to submit this article for publication.

Availability of data and materials

Not applicable.

Ethics approval and consent to participate

The study (including all information materials and forms for the written informed consent for patients and physicians) was approved by the Ethics Committee of the Albert-Ludwigs-University Freiburg (No. 380/18, vote from 22 of November, 2018). Informed consent of each patient is obtained in writing prior to participation.

Consent for publication

Not applicable. This manuscript does not contain any individual person's data.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Section of Health Care Research and Rehabilitation Research, Faculty of Medicine, University of Freiburg, Freiburg, Germany. ²Division of Infectious Diseases, Department of Medicine II, Medical Center –Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Received: 12 November 2019 Accepted: 30 December 2019

Published online: 14 January 2020

References

- Di Sabatino A, Carsetti R, Corazza GR. Post-splenectomy and hyposplenic states. *Lancet*. 2011;378(9785):86–97.
- Waghorn DJ. Overwhelming infection in asplenic patients: current best practice preventive measures are not being followed. *J Clin Pathol*. 2001; 54(3):214–8.
- Chong J, Jones P, Spelman D, Leder K, Cheng AC. Overwhelming post-splenectomy sepsis in patients with asplenia and hyposplenia: a retrospective cohort study. *Epidemiol Infect*. 2017;145(2):397–400.
- Holdsworth RJ, Irving AD, Cuschieri A. Postsplenectomy sepsis and its mortality rate: actual versus perceived risks. *Br J Surg*. 1991;78(9):1031–8.
- Edgren G, Almqvist R, Hartman M, Utter GH. Splenectomy and the risk of sepsis: a population-based cohort study. *Ann Surg*. 2014;260(6):1081–7.
- Spelman D, Buttery J, Daley A, Isaacs D, Jennens I, Kakakios A, et al. Guidelines for the prevention of sepsis in asplenic and hyposplenic patients. *Intern Med J*. 2008;38(5):349–56.
- Davies JM, Lewis MP, Wimperis J, Rafi I, Ladhani S, Bolton-Maggs PH, et al. Review of guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen: prepared on behalf of the British Committee for Standards in Haematology by a working party of the Haemato-Oncology task force. *Br J Haematol*. 2011;155(3):308–17.
- El-Alfy MS, El-Sayed MH. Overwhelming postsplenectomy infection: is quality of patient knowledge enough for prevention? *Hematol J*. 2004; 5(1):77–80.
- Langley JM, Dodds L, Fell D, Langley GR. Pneumococcal and influenza immunization in asplenic persons: a retrospective population-based cohort study 1990–2002. *BMC Infect Dis*. 2010;10:219.
- Gaston MH, Verter JJ, Woods G, Pegelow C, Kelleher J, Presbury G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial. *N Engl J Med*. 1986;314(25):1593–9.
- Wang J, Jones P, Cheng AC, Leder K. Adherence to infection prevention measures in a statewide spleen registry. *Med J Aust*. 2014;200(9):538–40.
- Theilacker C, Ludewig K, Serr A, Schimpf J, Held J, Bogelein M, et al. Overwhelming postsplenectomy infection: a prospective multicenter cohort study. *Clin Infect Dis*. 2016;62(7):871–8.
- Barg CJ, Latimer AE, Pomeroy EA, Rivers SE, Rench TA, Prapavessis H, et al. Examining predictors of physical activity among inactive middle-aged women: an application of the health action process approach. *Psychol Health*. 2012;27(7):829–45.
- Chiu CY, Lynch RT, Chan F, Berven NL. The health action process approach as a motivational model for physical activity self-management

- for people with multiple sclerosis: a path analysis. *Rehabil Psychol*. 2011;56(3):171–81.
15. Schwarzer R, Schuz B, Ziegelmann JP, Lippke S, Luszczynska A, Scholz U. Adoption and maintenance of four health behaviors: theory-guided longitudinal studies on dental flossing, seat belt use, dietary behavior, and physical activity. *Ann Behav Med*. 2007;33(2):156–66.
 16. Zhang CQ, Zhang R, Chung PK, Duan Y, Lau JTF, Chan DKC, et al. Promoting influenza prevention for elderly people in Hong Kong using health action process approach: study protocol. *BMC Public Health*. 2018;18(1):1230.
 17. Ernsting A, Gellert P, Schneider M, Lippke S. A mediator model to predict workplace influenza vaccination behaviour—an application of the health action process approach. *Psychol Health*. 2013;28(5):579–92.
 18. Payaprom Y, Bennett P, Alabaster E, Tantipong H. Using the health action process approach and implementation intentions to increase flu vaccine uptake in high risk Thai individuals: a controlled before-after trial. *Health Psychol*. 2011;30(4):492–500.
 19. Schwarzer R, Lippke S, Luszczynska A. Mechanisms of health behavior change in persons with chronic illness or disability: the health action process approach (HAPA). *Rehabil Psychol*. 2011;56(3):161–70.
 20. Arnott A, Jones P, Franklin LJ, Spelman D, Leder K, Cheng AC. A registry for patients with asplenia/hyposplenism reduces the risk of infections with encapsulated organisms. *Clin Infect Dis*. 2018;67(4):557–61.
 21. Moore GF, Audrey S, Barker M, Bond L, Bonell C, Hardeman W, et al. Process evaluation of complex interventions: Medical Research Council guidance. *BMJ*. 2015;350:h1258.
 22. Abraham C, Michie S. A taxonomy of behavior change techniques used in interventions. *Health Psychol*. 2008;27(3):379–87.
 23. Gundling F, Harms RT, Schiefke I, Schepp W, Mössner J, Teich N. Self assessment of warning symptoms in upper gastrointestinal bleeding. *Deutsches Aerzteblatt Online*. 2008.
 24. Hromek J. Prospektive Kohortenstudie zu Infektionskomplikationen und Prophylaxemaßnahmen bei Patienten nach Splenektomie; 2015.
 25. Kanhutu K, Jones P, Cheng AC, Grannell L, Best E, Spelman D. Splenic Australia guidelines for the prevention of sepsis in patients with asplenia and hyposplenism in Australia and New Zealand. *Intern Med J*. 2017;47(8):848–55.
 26. Staendige Impfkommision. Empfehlungen der Ständigen Impfkommision (STIKO) am Robert Koch-Institut. *Epid Bull*. 2017;34:333–80.
 27. Brenner M, Curbow B, West M. The proximal-distal continuum of multiple health outcome measures: the case of cataract surgery. *Med Care*. 1995; 33(4):AS236–AS44.
 28. Osborne RH, Elsworth GR, Whitfield K. The health education impact questionnaire (heiQ): an outcomes and evaluation measure for patient education and self-management interventions for people with chronic conditions. *Patient Educ Couns*. 2007;66(2):192–201.
 29. Schuler M, Musekamp G, Faller H, Ehlebracht-König I, Gutenbrunner C, Kirchoff R, et al. Assessment of proximal outcomes of self-management programs: translation and psychometric evaluation of a German version of the Health Education Impact Questionnaire (heiQ). *Qual Life Res*. 2013;22(6):1391–403.
 30. Osborne RH, Batterham RW, Elsworth GR, Hawkins M, Buchbinder R. The grounded psychometric development and initial validation of the health literacy questionnaire (HLQ). *BMC Public Health*. 2013;13:658.
 31. Scheibler F, Freise D, Pfaff H. Die Einbeziehung von Patienten in die Behandlung. *J Public Health*. 2004;12(3):199–209.
 32. Lerman C, Brody D, Caputo C, Smith D, Lazaro C, Wolfson H. Patients' perceived involvement in care scale: relationship to attitudes about illness and medical care. *J Gen Intern Med*. 1990;5:29–33.
 33. Morfeld M, Kirchberger I, Bullinger M. SF-36. Fragebogen zum Gesundheitszustand. Deutsche Version des Short Form-36 health Survey. Manual. 2., ergänzte und überarbeitete Auflage ed. Göttingen: Hogrefe Verlag GmbH & Co.KG; 2011.
 34. Wiesmann U, Timm A, Hannich H-J. Multiples Gesundheitsverhalten und Vulnerabilität im Geschlechtervergleich. *Zeitschrift für Gesundheitspsychologie*. 2003;11(4):153–62.
 35. Lowe B, Kroenke K, Grafe K. Detecting and monitoring depression with a two-item questionnaire (PHQ-2). *J Psychosom Res*. 2005;58(2):163–71.
 36. Kroenke K, Spitzer RL, Williams JB, Monahan PO, Loewe B. Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. *Ann Intern Med*. 2007;146:317–25.
 37. Meng K, Musekamp G, Schuler M, Seekatz B, Glatz J, Karger G, et al. The impact of a self-management patient education program for patients with chronic heart failure undergoing inpatient cardiac rehabilitation. *Patient Educ Couns*. 2016;99(7):1190–7.
 38. D'Agostino RB. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. *Statist Med*. 1998;17:2265–81.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions



COREQ (CONsolidated criteria for REporting Qualitative research) Checklist

A checklist of items that should be included in reports of qualitative research. You must report the page number in your manuscript where you consider each of the items listed in this checklist. If you have not included this information, either revise your manuscript accordingly before submitting or note N/A.

Topic	Item No.	Guide Questions/Description	Reported on Page No.
Domain 1: Research team and reflexivity			
<i>Personal characteristics</i>			
Interviewer/facilitator	1	Which author/s conducted the interview or focus group?	
Credentials	2	What were the researcher's credentials? E.g. PhD, MD	
Occupation	3	What was their occupation at the time of the study?	
Gender	4	Was the researcher male or female?	
Experience and training	5	What experience or training did the researcher have?	
<i>Relationship with participants</i>			
Relationship established	6	Was a relationship established prior to study commencement?	
Participant knowledge of the interviewer	7	What did the participants know about the researcher? e.g. personal goals, reasons for doing the research	
Interviewer characteristics	8	What characteristics were reported about the interviewer/facilitator? e.g. Bias, assumptions, reasons and interests in the research topic	
Domain 2: Study design			
<i>Theoretical framework</i>			
Methodological orientation and Theory	9	What methodological orientation was stated to underpin the study? e.g. grounded theory, discourse analysis, ethnography, phenomenology, content analysis	
<i>Participant selection</i>			
Sampling	10	How were participants selected? e.g. purposive, convenience, consecutive, snowball	
Method of approach	11	How were participants approached? e.g. face-to-face, telephone, mail, email	
Sample size	12	How many participants were in the study?	
Non-participation	13	How many people refused to participate or dropped out? Reasons?	
<i>Setting</i>			
Setting of data collection	14	Where was the data collected? e.g. home, clinic, workplace	
Presence of non-participants	15	Was anyone else present besides the participants and researchers?	
Description of sample	16	What are the important characteristics of the sample? e.g. demographic data, date	
<i>Data collection</i>			
Interview guide	17	Were questions, prompts, guides provided by the authors? Was it pilot tested?	
Repeat interviews	18	Were repeat interviews carried out? If yes, how many?	
Audio/visual recording	19	Did the research use audio or visual recording to collect the data?	
Field notes	20	Were field notes made during and/or after the interview or focus group?	
Duration	21	What was the duration of the interviews or focus group?	
Data saturation	22	Was data saturation discussed?	
Transcripts returned	23	Were transcripts returned to participants for comment and/or	

Topic	Item No.	Guide Questions/Description	Reported on Page No.
		correction?	
Domain 3: analysis and findings			
<i>Data analysis</i>			
Number of data coders	24	How many data coders coded the data?	
Description of the coding tree	25	Did authors provide a description of the coding tree?	
Derivation of themes	26	Were themes identified in advance or derived from the data?	
Software	27	What software, if applicable, was used to manage the data?	
Participant checking	28	Did participants provide feedback on the findings?	
<i>Reporting</i>			
Quotations presented	29	Were participant quotations presented to illustrate the themes/findings? Was each quotation identified? e.g. participant number	
Data and findings consistent	30	Was there consistency between the data presented and the findings?	
Clarity of major themes	31	Were major themes clearly presented in the findings?	
Clarity of minor themes	32	Is there a description of diverse cases or discussion of minor themes?	

Developed from: Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. *International Journal for Quality in Health Care*. 2007. Volume 19, Number 6: pp. 349 – 357

Once you have completed this checklist, please save a copy and upload it as part of your submission. DO NOT include this checklist as part of the main manuscript document. It must be uploaded as a separate file.

BMJ Open

Asplenic patients' and doctors' experiences in implementing preventative measures following a novel educational intervention: a qualitative analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-060492.R1
Article Type:	Original research
Date Submitted by the Author:	21-Sep-2022
Complete List of Authors:	Anka, Natascha; University of Freiburg Faculty of Medicine, Section of Health Care Research and Rehabilitation Research Glattacker, Manuela ; University of Freiburg Faculty of Medicine, Section of Health Care Research and Rehabilitation Research Farin-Glattacker, Erik; University of Freiburg Faculty of Medicine, Section of Health Care Research and Rehabilitation Research Camp, Johannes; University of Freiburg Faculty of Medicine, Division of Infectious Diseases, Department of Medicine II Rieg, Siegbert; University of Freiburg Faculty of Medicine, Division of Infectious Diseases, Department of Medicine II Bayrhuber, Marianne; University of Freiburg Faculty of Medicine, Section of Health Care Research and Rehabilitation Research
Primary Subject Heading:	Qualitative research
Secondary Subject Heading:	Immunology (including allergy), Medical education and training, Patient-centred medicine
Keywords:	PREVENTIVE MEDICINE, QUALITATIVE RESEARCH, INFECTIOUS DISEASES, MEDICAL EDUCATION & TRAINING

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 1 **Asplenic patients' and doctors' experiences in implementing preventative measures**
4
5 2 **following a novel educational intervention: a qualitative analysis**
6

7 3
8
9 4 Natascha Anka^{1*}: natascha.anka@uniklinik-freiburg.de

10
11 5 PD Dr. Manuela Glattacker¹: manuela.glattacker@uniklinik-freiburg.de

12
13 6 Prof. Dr. Erik Farin-Glattacker¹: erik.farin@uniklinik-freiburg.de

14
15 7 Dr. Johannes Camp²: johannes.camp@uniklinik-freiburg.de

16
17 8 Prof. Dr. Siegbert Rieg²: siegbert.rieg@uniklinik-freiburg.de

18
19 9 Dr. Marianne Bayrhuber¹: marianne.bayrhuber@uniklinik-freiburg.de

20
21
22 10

23
24 11 *First author

25
26 12

27
28 13 ¹ Section of Health Care Research and Rehabilitation Research, Faculty of Medicine,
29
30 University of Freiburg, Freiburg, Germany

31
32 15 ² Division of Infectious Diseases, Department of Medicine II, Medical Center – Faculty of
33
34 Medicine, University of Freiburg, Freiburg, Germany

35
36
37 17

38
39 18 **Corresponding author**

40
41 19 Dr. Marianne Bayrhuber

42
43 20 Section of Health Care Research and Rehabilitation Research

44
45 21 Faculty of Medicine, University of Freiburg

46
47 22 Hugstetter Straße 49

48
49 23 79106 Freiburg

50
51 24 Germany

52
53 25 Phone: +49 761 270 83734

54
55 26 E-Mail: marianne.bayrhuber@uniklinik-freiburg.de

56
57 27

58
59 28 Word count (excluding title page, abstract, references, figures and tables): 5314

29 ABSTRACT

30 **Objective:** To explore asplenic patients' and GPs' (1) perceptions of a novel, *Health Action*
31 *Process Approach* (HAPA)-based, educational intervention which targets to increase
32 adherence to post-splenectomy sepsis (PSS) prevention measures and (2) their experience in
33 implementing prevention measures following this intervention.

34 **Design:** A process evaluation conducted on average 3.5 (for patients) and 3.8 (for GPs)
35 months after the intervention between January 2020 and April 2021 individually by means of
36 semi-structured guideline-based telephone-interviews. Data was analysed using qualitative
37 content analysis.

38 **Participants:** Volunteer sub-sample of N = 25 asplenic patients and N = 8 GPs who received
39 the intervention. Inclusion criteria were met by prior participation in the intervention (German-
40 speaking, of full age and insured by the cooperating health insurance). Patient selection was
41 done by purposeful selection aiming at maximum variability in terms of adherence to
42 preventative measures prior to intervention participation. Participating GPs are a non-
43 purposeful selected convenience sample. For reasons of data protection, no personal data
44 was collected.

45 **Results:** The intervention was positively evaluated and its personal relevancy for patients and
46 for the GPs' professional work became apparent. The intervention promoted risk awareness,
47 intention to action, action planning and subsequently, improved adherence to preventative
48 measures. Helpful factors for implementation among the patients were social support by
49 relatives and GPs. Barriers to adherence identified in both groups can be divided into patient-
50 attributed (e.g. comorbidities), doctor-related (e.g. lack of knowledge or support) as well as
51 contextual factors (e.g. vaccine supply constraints).

52 **Conclusions:** Our findings indicate a patient and GP perceived benefit of the intervention, but
53 still identify prevailing barriers to implementation. In a further step, a quantitative evaluation of
54 the intervention will be conducted and recommendations for integrating the intervention in
55 usual care will be made.

1
2
3 56 **Trial registration:** German Clinical Trials Register (DRKS): DRKS00015238; Trial registration
4
5 57 date is 7th December 2018.
6
7 58

9 59 **Keywords:** Asplenia, Post-splenectomy sepsis (PSS), Sepsis, Splenectomy, General
10
11 60 practitioners (GPs), Prevention, Intervention, Health Action Process Approach (HAPA),
12
13 61 Interviews, Qualitative Content Analysis, Barriers
14
15
16
17

18 62 **Article Summary**

19
20 63 Strengths and limitations of this study

- 21
22 64 • This is the first study in the field of asplenia that explores in depth patients' and GPs'
23
24 65 experiences in implementation of PSS preventative measures following an intervention
25
26 66 intended to increase adherence.
27
28 67 • Purposeful selection of patients which aimed at maximum variation regarding their pre-
29
30 68 interventional adherence enabled to explore a sample with diverse initial experiences in
31
32 69 preventative behaviour.
33
34 70 • A minor limitation as regards to the intended maximum variation selection is that very high
35
36 71 levels of adherence did not occur in the sample.
37
38 72 • Since participation in the interview, which serves as the data basis in this study, was a
39
40 73 voluntary additional effort, a positive bias might have been induced.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

75 INTRODUCTION

76 Patients with an absent or dysfunctional spleen are susceptible to infectious diseases
77 throughout their lives and are at an increased risk of developing an post-splenectomy sepsis
78 (PSS; also called overwhelming post-splenectomy infection, abbr. OPSI)[1], with a mortality
79 rate up to 50%[2]. According to international clinical guidelines, OPSI is largely preventable
80 through prophylactic measures in this patient population[3]. These measures include amongst
81 others anti-pneumococcal and anti-meningococcal vaccination, permanent availability of a
82 medical alert card and an antibiotic supply for emergency fever treatment ('pill in the pocket')
83 as well as patient education.

84 However, there is widespread evidence, that guideline awareness and adherence are low[1].
85 Even if the doctor's knowledge and attitude towards guidelines was found to be appropriate,
86 patient education by health providers as well as inter-sectorial communication were described
87 as insufficient[4]. Thus, many asplenic patients have poor knowledge about the risk associated
88 with their condition and existing prevention recommendations[i.a. 5-7]. Beyond these
89 knowledge (transfer) gaps mainly reported in literature, barriers such as safety concerns,
90 scepticism and the doubted need for vaccination are further reasons that were found for
91 asplenic patients' non-adherence[8]. As better patient knowledge can be considered a key
92 factor in improving adherence[9], and primary care providers are critical in patient education
93 and prevention implementation[8, 10], we developed a novel educational intervention for both
94 asplenic patients and for their general practitioners (GPs) (for a detailed description of the
95 intervention see[11]).

96 The intervention is a manual-based individualised telephone counselling on evidence-based
97 information of the spleen, asplenia-related infection risks and infection prevention
98 recommendations, conducted by an infectious diseases specialist. The *Health Action Process*
99 *Approach* (HAPA), a framework that provides predictors for initiation and maintenance of
100 preventative behaviour[12], including vaccination behaviour[i.a. 13], served as theoretical
101 basis. Distinguished into two phases in the HAPA, these predictors include risk perception,
102 outcome expectancies and perceived task self-efficacy which influence the formation of an

1
2
3 103 intention (*motivational phase*) as well as action and barrier coping planning and maintenance
4
5 104 self-efficacy that lead to the actual behaviour (*volitional phase*). Accordingly, our intervention
6
7 105 includes specific components which promote motivation for initiation as well as action-related
8
9 106 strategies such as planning and managing barriers, the latter being realised through a
10
11 107 customisable action plan for patients. For doctors, the intervention is primarily information-
12
13 108 orientated by conveying current guideline recommendations for asplenic patients in general
14
15 109 and the attending patient specifically. Accompanying the telephone intervention, participants
16
17 110 receive written information tailored both to patient and doctor, along with a plain vaccination
18
19 111 schedule and a medical alert card.
20
21
22 112 The intervention is currently being evaluated in terms of its effectiveness in a two-armed
23
24 113 historical control-group design. Moreover, as recommended for complex interventions[14], the
25
26 114 intervention was evaluated in a qualitative process evaluation. The findings of the process
27
28 115 evaluation will be reported in the present article, the quantitative findings will be reported
29
30 116 elsewhere. The aim of the process evaluation is to investigate how patients and doctors
31
32 117 evaluate the intervention and how they perceive its usefulness for implementation, with
33
34 118 particular attention to health behaviour changing factors according to HAPA. And notably, the
35
36 119 objective is to gain a deeper understanding of the participants' experience in implementing the
37
38 120 preventative measures post-intervention, including factors that influence adherence, that are
39
40 121 subjectively perceived barriers as well as helpful factors.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

122 METHODS

123 **Study design**

124 This is a qualitative interview-study conducted with asplenic patients and attending GPs. To
125 ensure the reliability and rigor of our results the methods and the findings are presented in
126 accordance with the consolidated criteria for reporting qualitative research (COREQ)
127 checklist[15] (See supplementary file 1). The research design was based on two steps: 1) A
128 semi-structured interview guideline according to Helfferich (2011) [16] was developed in a
129 multi-step process under comprehensive review of the whole team (See supplementary file 2
130 for interview guidelines). The interviews were audio-recorded and fully transcribed by an
131 external service provider and also anonymized in this step. 2) The content analysis was
132 computer-assisted using MAXQDA Plus 2020 (version 20.0.3). In order to ensure the reliability
133 and credibility of the analysis we followed the qualitative content analysis based on the
134 approach of Kuckartz [17].

135 **Patient and public involvement**

136 Patients or the public were not actively involved in this research.

137 **Participants and recruiting**

138 The sample is a sub-sample of asplenic patient and doctor participants, who received the
139 intervention and were willing to take part in an additional interview (willingness was queried
140 after participation in the intervention on the phone). Inclusion criteria for patients were met by
141 prior study participation (these were German-speaking, of full age and insured by the
142 cooperating AOK health insurance; see[11]). All interviewees provided written informed
143 consent to participate, including having their interview audiotaped and further processed. They
144 received a 30 € voucher for participation. For reasons of data protection, no personal data was
145 collected.

1
2
3 146 Patient participants

4
5 147 Patients were selected using a maximum variation sampling approach (purposeful sampling).

6
7 148 A maximum variability in terms of their pre-interventional study-specific 'Preventing PSS-score'

8
9 149 ('PrePSS-score') was sought. The 'PrePSS-score' indicates patients' adherence to the

10
11 150 recommended preventative measures on a scale from 0 to 10 (anti-pneumococcal and anti-

12
13 151 meningococcal vaccination, availability of a medical alert card and of an antibiotic supply; for

14
15 152 details on development and calculation of the 'PrePSS-score' see[11]), with higher scores

16
17 153 indicating greater adherence. With this approach, we expected to explore diverse experiences

18
19 154 in implementation as those might differ according to prevention measures taken prior to the

20
21 155 study participation.

22
23 156 Selection was performed in two phases. Firstly, all the patients who had agreed to participate

24
25 157 were selected successively. After conducting initial N=14 interviews, further patients were

26
27 158 purposively selected in an iterative process on the basis of so far unrepresented or

28
29 159 underrepresented preinterventional 'PrePSS-score' to obtain maximum variation. Appropriate

30
31 160 maximisation was assumed when each possible 'PrePSS-score' (0-10) occurred at least twice.

32
33 161 Thus, this approach was also used to determine the minimum number of interviews necessary.

34
35 162 Since the values 7, 9 and 10 did not occur among patients who were willing to participate, the

36
37 163 range of variation was determined by the actual scores present for this sub-group (for exact

38
39 164 frequencies see Table 1).

40
41 165 In total N=31 patients were contacted. As N=6 of them did not provide written consent (N=1

42
43 166 refused participation due to ongoing treatment, N=5 could not be reached), N=25 patients were

44
45 167 interviewed. That is 22.7% of all patients (N=110) who received the intervention.

46
47 168

48
49 169 Table 1 *Frequencies of the preinterventional 'PrePSS-score' of the participants*

PrePSS-score (0-10)	N	%
0	1	4
1	4	16
2	5	20
3	3	12

4	4	16
5	3	12
6	3	12
7	0	0
8	2	8
9	0	0
10	0	0

170

171 Doctor participants

172 Due to low participation willingness and difficulties with accessibility (presumably in part
 173 because this study was conducted during the COVID-19-pandemic) a non-purposeful selection
 174 procedure was required for the doctors. We took a convenience sample of doctors, i.e. all
 175 those who were willing to participate (N=11) were contacted for study participation. Among
 176 these, N=8 participated. The remaining N=3 participants were not reachable (N=2) or refused
 177 participation due to lack of time (N=1). Participating doctors were the GPs of any of the
 178 intervention group patients. Thus, patients and doctors were not chosen in pairs for the
 179 interviews.

180 Interview guideline

181 The semi-structured interview guidelines for patients and doctors were drafted by N.A und M.B.
 182 following Helfferich (2011)[16] and finalised after review by the whole study team. Marginal
 183 adjustments to improve applicability were made upon mutual agreement between the
 184 interviewers after 14 patient interviews were conducted.

185 The interview guide for patients was divided into three obligatory main blocks on the topics (a)
 186 'evaluation of the telephone intervention' (initial question), (b) 'experience in implementing
 187 preventative measures' and (c) 'dealing with sepsis risk' and (d) a supplementary block
 188 addressing the written information material accompanying the telephone intervention. Each
 189 question block contained an open-ended obligatory core question that subsumed the key
 190 aspects of each topic. Interviewees were to be given the opportunity to freely report on their
 191 experiences, specific questions were only posed if a relevant aspect of the core topic was not

1
2
3 192 proposed by the participants. The interview guide for doctors contained the topics (a)
4
5 193 'evaluation of telephone intervention' (initial question), (b) 'usefulness of the telephone
6
7 194 intervention' and (c) a question block addressing the written information material. Overall, the
8
9 195 doctor interview guide was more information-orientated compared to the patients' guide, and
10
11 196 improvement suggestions were directly requested from doctors. The interview guidelines are
12
13
14 197 attached in supplementary file 2.
15
16 198

19 199 **Procedure and transcription**

20
21 200 Patients and doctors were interviewed individually between January 2020 and April 2021 via
22
23 201 telephone by M.B. and N.A. using the developed guideline. M.B. and N.A., both female
24
25 202 research assistants and psychologists with experience in counselling and conversation
26
27 203 techniques were responsible for the development of the guidelines and the implementation
28
29 204 and analysis of the interviews. They were also involved in the development of the manuals for
30
31 205 the patient and doctor-directed interventions. Apart from a short telephone contact to arrange
32
33 206 the interview date, the interviewers did not know the interviewees beforehand. They introduced
34
35 207 themselves as part of the study team responsible for evaluating the intervention. Participants
36
37 208 were informed that the study-doctor who conducted the telephone intervention would have no
38
39 209 access to recordings or transcripts of individual patient interviews, but only to aggregated, pre-
40
41 210 processed data of all the interviewees.
42
43

44 211 The interview dates were scheduled about 3 months after the telephone intervention. For
45
46 212 practical reasons, this period between the intervention and the interview varied between 2.5
47
48 213 and 6.5 months (on average 3.5 months) among the patients. For the doctors, the time period
49
50 214 varied between 2.5 and 7.3 months (on average 3.8 months). All interviews were digitally
51
52 215 audio-taped in full. No field notes were taken during the interview. The audio recordings were
53
54 216 transcribed verbatim by an external transcription service provider. Personal data were
55
56 217 pseudonymised before data analysis. Neither transcripts nor results were returned to
57
58 218 participants for feedback.
59
60 219

220 **Data analysis**

221 The transcripts of the interviews were analysed using qualitative content analysis largely based

222 on the approach of Kuckartz (2018)[17], which involves both deductive and inductive coding.

223 The chosen multi-level procedure for this study is outlined in Table 2.

224

225 Table 2 *Levels of the qualitative content analysis*

Familiarisation stage	Before coding, the entire transcribed text material was read intensively in the process of pseudonymisation and short case summaries were composed.
Inductive-deductive development of the initial coding frame	Based on this familiarisation stage, codes were extracted inductively by N.A. In a next step, additional codes were derived deductively from key topics of the interview guideline, from previous research on barriers that influence patients' adherence to preventative measures [18] and from the underlying theoretical HAPA.
Quota sample trial phase and revision	This initial coding frame was then applied to a quota sample consisting of 20% of the data material (N=5 patient and N=2 doctor interview transcripts), comprising interviews from both interviewers collected at various time points during data collection. In the process of this trial phase, the codes were refined several times through continuous reflection and classified into main and sub-codes.
Entire data material trial phase and team-review	This was followed by the first coding of the entire data material along the so far defined coding frame. In this process, codes were again revised if required, e.g. summarised or differentiated into further sub-codes. In this process a coding guideline was formulated. To ensure intersubjective comprehensibility, the coding frame, the guideline and the coding of individual, randomly chosen interviews were critically reviewed by M.B., M.G. and E.F. and, if needed, slightly adapted to their feedback. This resulted in the final set of six main codes and 11 sub-codes for patients and four main codes and four sub-codes for doctors (for an overview see Table 3 and 4).
Application of the final coding system	This final coding system was then applied to the entire data material by N.A.
Extraction of a code x participant-summary-matrix	In the last step, all the statements of a participant assigned to the same code were paraphrased and the overall findings were extracted from a code x participant-summary-matrix.

226

227 Data organisation and analysis was performed using MAXQDA Plus 2020 (version 20.0.3)

228 qualitative data analysis software. Following quantitative descriptive information was

229 calculated using IBM SPSS Statistics (version 27). The entire patient data material to be

230 analysed had covered a duration of about 712 minutes, the data material of doctors circa 148

231 minutes. The patient interviews lasted between 9 and 75 minutes, with an average length of

232 28 minutes; doctor interviews lasted between 7 and 30 minutes, on average 18 minutes. The

233 interviews were conducted in German. Code descriptions and quotations taken from the

234 interview transcripts given below are translations from German into English (Table 3 and 4).

235

236 Table 3 *Final coding system of patients' interviews*

Main codes	Sub-codes
Implementation of preventative measures	
Barriers to implementation of preventative measures	
Perceptions of the intervention	<i>Evaluation of the telephone intervention and accompanying information material</i> <i>Personal relevance of the intervention</i>
Perceived impact and usefulness of the intervention for implementation	<i>Implementation of preventative measures</i> <i>Motivation for implementation</i> <i>Initiation and maintenance of steps necessary for implementation</i> <i>Initiation and maintenance of implementation through prior planning</i> <i>Perceived effects of the intervention on the GP</i>

Infection-related risk perception following the intervention	<i>Cognitive-affective level</i>
	<i>Behavioural level</i>
Barriers and helpful factors for implementation of preventative measures following the intervention	<i>Barriers to implementation</i>
	<i>Helpful factors: social support</i>

237

238

239

Table 4 *Final coding system of doctors' interviews*

Main codes	Sub-codes
Barriers to implementation of preventative measures	<i>Evaluation of the telephone intervention and accompanying information material</i>
Perceptions of the intervention	<i>Relevance of the intervention for own professional work</i>
Perceived impact and usefulness of the intervention for implementation	<i>Implementation of preventative measures</i>
	<i>Perceived impact on further medical action</i>
Barriers to implementation of preventative measures following the intervention	

240

241 **FINDINGS**242 **Patients' interviews**

243 Implementation of preventative measures

244 Only few patients made reference to prevention measures that had been implemented prior to

245 study participation, with most of them indicating initial approaches and none the full

1
2
3 246 implementation of recommendations. Patients reported having already received (some or all
4
5 247 of) the recommended initial vaccinations. These vaccinations had been administered post-
6
7 248 splenectomy by the hospital conducting the splenectomy, after discharge by the GP, a
8
9 249 specialist or during rehab and, in two cases of elective surgery, even before the splenectomy.
10
11 250 Furthermore, a few patients stated that they had already received a medical alert card for
12
13 251 asplenic patients from hospital, which, however in some cases were not filled out completely
14
15 252 or not permanently available.

16
17
18
19 253 *'I have had only, I think, two vaccinations. And then they said that it was done. I then took the*
20
21 254 *list, presented it to him and then I got the rest of the vaccinations.'* [ID240216]

22
23
24
25 255 Barriers to implementation of preventative measures

26
27 256 Regarding barriers to implement preventative measures, personal, contextual, as well as
28
29 257 doctor-attributed factors could be found. The majority of patients mentioned their own
30
31 258 insufficient or complete lack of knowledge about the infection risk associated with asplenia and
32
33 259 (the need for) corresponding preventative measures. Poor relevant knowledge and failures in
34
35 260 implementation were largely attributed to the GP, to the hospital or the rehab centre (or their
36
37 261 cooperation), with patients stating that they were either inadequately, incorrectly,
38
39 262 incomprehensibly or not at all educated and patients assumed that a lack of relevant
40
41 263 knowledge, time or priority by the health care providers were the reasons.

42
43
44 264 *'However, the hospital staff said that everything was okay and that it was possible to live*
45
46 265 *without a spleen.'* [ID020314]

47
48
49 266 Furthermore, comorbidity (mostly cancer) and/or the poor health condition of patients
50
51 267 influenced measure implementation as disease-related fears and treatments gave less priority
52
53 268 to vaccinations necessitated by the splenectomy or were the reason for their temporary
54
55 269 contraindication. Contextual barriers included vaccine supply difficulties and vaccine costs
56
57 270 considered not being borne by the health insurance. The results presented below refer to the
58
59 271 intervention and to experiences following the intervention.

1
2
3 272 Perceptions of the intervention
4

5 273 *Evaluation of the telephone intervention and accompanying information material*
6

7 274 As regards the evaluation of the telephone intervention, a relatively homogeneous picture
8
9 275 emerged. Respondents experienced it as pleasant, patient-centred and some mentioned they
10
11 276 felt taken care of. The information provided was evaluated as being informative and
12
13 277 comprehensible (except for some of the technical terms and abbreviations used). Duration was
14
15 278 deemed appropriate and necessary. As to the information material, patients stated they made
16
17 279 use of it and some kept it to be able to refer to it at any time. It was rated as informative (in
18
19 280 particular the vaccination schedule included) and comprehensible. However, some people
20
21 281 clearly expressed the added value of the telephone intervention aligned to the written
22
23 282 information material over only having the information material, especially when considering
24
25 283 comprehension.
26
27
28

29 284 *'So that was pleasant for me. I could ask him questions, he calmed me down and, yes, it was*
30
31 285 *understandable.'* [ID020314]
32
33

34 286 *Personal relevance of the intervention*
35

36 287 Beyond the evaluation of the intervention, its personal relevancy for the participating patients
37
38 288 became apparent. Interviewees were appreciative of having received previously unknown or
39
40 289 incomplete disease-specific information they rated as subjectively important. They stated that
41
42 290 their awareness of risk factors and necessary prevention was formed or increased by the (new)
43
44 291 information and some reported they felt safer having been educated now.
45
46

47 292 *'And I have to say, it has also given me a sense of security. And the education was very good,*
48
49 293 *because, as I said before, I had no idea [...]'* [021310]
50
51
52

53 294 Impact and usefulness of the intervention for implementation
54

55 295 *Implementation of preventative measures*
56

57 296 All the respondents who provided information on immunisation had received the recommended
58
59 297 vaccinations since the telephone intervention or had already planned outstanding (or booster)
60

1
2
3 298 vaccinations. The medical alert card and the antibiotics for emergency treatment were also
4
5 299 mostly permanently available to patients (left in the car, handbag, wallet or mobile phone case),
6
7 300 even though there were some failures in filling the alert card in.
8
9

10 301 *'I have got antibiotics for emergency treatment, meantime. I always carry it with me when I go*
11
12 302 *away [...] I have the medical alert card with me all the time.'* [ID 021311]
13
14

15 303 *Motivation for implementation*

16
17 304 Some participants explicitly expressed that the intervention had nudged them to plan,
18
19 305 implement or adhere to preventative measures or to demand implementation from their GP.
20
21

22
23 306 *'[...] that the thought process started for me, what do I have to pay attention to for myself?*

24
25 307 *What do I need to make my general practitioner aware of?'* [ID090709]
26
27

28 308 Aside from that, three interviewees made reference to the influenza vaccination, which they
29
30 309 had never received before, but were convinced of its necessity due to the telephone
31
32 310 consultation.
33
34

35 311 *Initiation and maintenance of steps necessary for implementation*

36
37 312 A large proportion of patients said that they had seen their GP following the telephone
38
39 313 intervention to inform him or her of their participation in the study, of required preventative
40
41 314 measures and to demand their implementation. Among other things, patients themselves (co-
42
43 315)monitored and organised vaccine supply, vaccination dates and sequence and some partially
44
45 316 filled in the medical alert card. In order to keep track of vaccination boosters and expiration
46
47 317 dates of the antibiotics, some reported making use of calendar reminders or other notes.
48
49

50 318 *'It's more in the direction of my family doctor that I keep at it, that it continues. There are also*
51
52 319 *problems with the supply of vaccines.[...] And these are currently the issues that are keeping*
53
54 320 *me busy at the moment. I just have to make sure that I get through my vaccination schedule*
55
56 321 *and that I can also tick it off.'* [ID090709]
57
58
59
60

1
2
3 322 *Initiation and maintenance of implementation through prior planning*

4
5 323 Some interviewees stated that they followed the individual action plan they had established
6
7 324 during the telephone intervention prompted by the study doctor and that they made use of the
8
9 325 corresponding worksheet to monitor implemented and pending preventative measures.

10
11
12 326 *Perceived effects of the intervention on the GP*

13
14 327 During a consultation following the telephone intervention, patients reported that they
15
16 328 perceived their GPs being open to the (new) information and to study (participation).
17
18 329 Preventative measures would have taken an unprecedented priority as most doctors supported
19
20 330 the implementation by initiating or monitoring the process (e.g. deposited study information,
21
22 331 arranged vaccine supplies, reminders about (booster) vaccinations, or completion of the
23
24 332 medical alert card).

25
26
27
28 333 *'So, I have the impression that he's already got this properly on the agenda, to pursue it now*
29
30 334 *and also to take it further. [...]. And I attribute this to the conversation with you.'* [ID090709]

31
32
33 335 It has to be mentioned here, that, to the patient's knowledge, some of the GPs had received
34
35 336 the telephone intervention for doctors at the time of the patient interview and others had not
36
37 337 (yet).

38
39
40 338 Infection-related risk perception following the intervention

41
42 339 *Cognitive-affective level*

43
44 340 Some patients indicated that they had (initially) been alarmed, concerned or anxious when
45
46 341 receiving (largely) unfamiliar information on the asplenia-related infection and sepsis risk
47
48 342 through the intervention. Some described being uncertain about potential risk factors and signs
49
50 343 of sepsis as well as about whether they, in case of infection, would react properly. There were
51
52 344 also patients who were quite optimistic and unconcerned. Some of these (as well as some of
53
54 345 those who stated they were initially concerned) said that they felt safe and prepared to deal
55
56 346 with the existing risk thanks to comprehensive education, as well as through preventative
57
58 347 measures (to be) taken and knowledge of their efficacy.
59
60

1
2
3 348 *'Because before that, it was rather in abeyance. I just read and heard: Yes, blood poisoning,*
4
5 349 *far, far greater risk. [...]. However, after that [telephone intervention] it was a bit better [...]. So,*
6
7 350 *I don't imagine now my hand suddenly falling off from one second to the next.'* [ID021012]
8
9

10 351 *Behavioural level*

11
12 352 Besides the cognitive and affective consequences of risk perception, respondents also
13
14 353 adapted their behaviour following the intervention. Beyond implementation of the main
15
16 354 preventative measures, patients showed precautionary behaviour (i.e. avoiding crowds,
17
18 355 keeping their distance from potentially sick people, wearing face masks, being careful about
19
20 356 hand-hygiene, avoiding injuries and if needed seeing a doctor sooner) or were alert for
21
22 357 symptoms. Some interviewees made direct reference to the current COVID-19-pandemic,
23
24 358 which probably had enhanced or induced caution.

25
26
27
28 359 *'I'm also paying more attention to myself now, even more. And I check every day, is there*
29
30 360 *anything that doesn't belong there? This line or am I warm and have high temperature, [...].'*
31
32 361 [ID120714]
33
34

35
36 362 Barriers and helpful factors for implementation following the intervention

37
38 363 *Barriers to implementation*

39
40 364 For implementation of the targeted preventative measures following the intervention, again
41
42 365 personal, contextual as well as doctor-attributed barriers were depicted. The most common
43
44 366 personal reason for delayed or prolonged implementation of (booster) inoculations was
45
46 367 comorbidity (ongoing chemotherapy or immune treatment), less often mentioned was the
47
48 368 personal refusal of the influenza vaccination. Doctor-attributed barriers were poor support in
49
50 369 initiating and administering vaccinations, inadequate education about side effects by or
51
52 370 confusion about the vaccination sequence. Other barriers were vaccine supply shortages,
53
54 371 difficulties in appointment availability and coordination and, in one case, vaccination costs that
55
56 372 were assumed to not be covered by the health insurance. Concerning the medical alert card,
57
58 373 a few interviewees stated that they were not able to complete it themselves, with some GPs
59
60

1
2
3 374 refusing to help. One patient expressed discomfort at having to manage and carry several
4
5 375 (vaccination attesting) documents.

6
7
8 376 *'What I found a pity was that I often presented the medical alert card to my doctor, to my family*
9
10 377 *doctor, but they didn't want it at all... in fact, they didn't even look at it.'* [ID041710]

11
12
13 378 Reasons for not having antibiotics available for emergency treatment were lacking (patient or
14
15 379 doctor) conviction or knowledge of individual need, as well as lack of cooperation of the GP.
16
17 380 In another case, a patient criticised that her GP did not educate her about the use (including
18
19 381 dosage) of the prescribed antibiotic.

20
21
22 382 *Helpful factors: social support*

23
24 383 A good relationship, experienced general support, as well as professional advice and care by
25
26 384 the GP (and the GP co-workers) were mentioned as a helpful factor in prevention
27
28 385 implementation and in coping with their condition by many interviewees. Among other things,
29
30 386 it seemed to be of great significance for patients to be able to rely on their GP for (prospective)
31
32 387 measure implementation. A large proportion also felt supported emotionally and in prevention
33
34 388 implementation by their relatives (thanks to accompaniment to doctor's appointments, for
35
36 389 example). Some subjects actively involved family members (in one case also colleagues) by
37
38 390 informing them about the disease specifics and preventative measures necessary or already
39
40 391 taken (e.g. depository of emergency antibiotic supply).

41
42
43
44 392 *'My husband also knows about it. Yes, of course, I told him all this too. And he has read*
45
46 393 *everything that he has received. He is also always with me at the doctor.'* [ID120714]

47
48
49
50 394 Doctors' views

51
52
53
54 395 Barriers to implementation of preventative measures

55
56 396 For implementation of the preventative measures prior to study participation, interviewed
57
58 397 doctors mentioned both doctor (i.e. own) and health care system-related barriers as well as
59
60 398 patient-attributed barriers. Most notably, interviewees described own knowledge gaps or

1
2
3 399 uncertainties when it comes to asplenia-specific risks, updated vaccination recommendations
4
5 400 or the necessity of an antibiotic prophylaxis and some made reference to their minimal routine
6
7 401 in the treatment of this patient group. Furthermore, two doctors described deficits at the
8
9 402 hospital-outpatient care interface, on the part of the hospital (e.g. misleading information in the
10
11 403 discharge letter, lack of raising patients awareness of further out-patient care by GP) as well
12
13 404 as the own lack of awareness and assumed patient's failures.

15
16 405 *'And that is my mistake, the patient's mistake, and at the same time the [name of hospital]'s*
17
18 406 *mistake is also present, a hundred percent. All the stops have not been pulled out properly.'*
19
20
21 407 *[ID072212]*

22
23
24 408 Perceptions of the intervention

25
26 409 *Evaluation of the telephone intervention and accompanying information material*

27
28 410 The intervention was overall positively evaluated by all the GPs interviewed. The telephone
29
30 411 based intervention was viewed as pleasant, instructive and individually-adapted to prior
31
32 412 knowledge and the attending patient. The duration of the phone call was viewed as
33
34 413 appropriate. Accompanying information material was mostly used and/or deposited for future
35
36 414 recourse, content was evaluated as helpful and the scope (with one exception) as adequate.
37
38 415 Still, all the GPs gave preference to the telephone consulting over only written information
39
40 416 material (in terms of raising awareness and the opportunity to discuss aspects in depth).

41
42
43
44 417 *'O.k., I found it pleasant, very informative and very individual. He was very responsive to my*
45
46 418 *previous knowledge, I had also read something before.'* *[ID050610]*

47
48
49 419 *Relevance of the intervention for own professional work*

50
51 420 Beyond formal evaluation, the GPs addressed the effect of the intervention for their work. They
52
53 421 stated that they received subjectively new or up-dated information on asplenic preventative
54
55 422 care, classified as reliable (expert knowledge) and helpful for the treatment of their patients.
56
57 423 Besides knowledge (-reactivation), they mentioned increased attention to their (further)
58
59
60

1
2
3 424 patients affected and their own responsibility in implementing and monitoring (e.g. when it
4
5 425 comes to booster vaccinations, periodic renewal of antibiotic prescriptions) the precautions.
6
7

8 426 *'So we already knew what we had to do in case of asplenia, but we still hadn't had it on our*
9
10 427 *minds that much.'* [ID042812]
11
12

13
14 428 Impact and usefulness of the intervention for implementation

15
16 429 *Implementation of preventative measures*

17
18 430 GPs mentioned preventative measures already implemented or ongoing, mostly in terms of
19
20 431 vaccinations. Since the systematic record of their factual implementation was not the aim of
21
22 432 this interviews, but rather the experience of it, corresponding responses remained quite vague
23
24 433 and rare.

25
26
27 434 *'So she got the medical alert card from you, and, I think I gave her a prescription for the stand-*
28
29 435 *by antibiotic right away.'* [ID072212]
30
31

32 436 *Perceived impact on further medical action*

33
34 437 Besides implementation of the measures themselves, GPs also named heterogeneous other
35
36 438 consequences for their work. For instance, adaption of vaccination schedules and templates
37
38 439 for doctor's letters, storing of patients' asplenia-specific information in the internal system,
39
40 440 targeted summoning and broader education of affected patients as well as a more extensive
41
42 441 diagnostic work-up in the case of infections.
43
44

45
46 442 *'When infections occur I become alert and I immediately think, should I treat it with antibiotics*
47
48 443 *now, maybe I need to do a bit more diagnostics than usual?'* [ID050610]
49
50

51 444 Barriers to implementation of preventative measures following the intervention

52
53 445 As regards the implementation of the preventative measures following the intervention, doctors
54
55 446 (i.e. own), health care system-related and patient-attributed barriers as well as contextual
56
57 447 factors were described by interviewed GPs. Doctor-attributed barriers to vaccination were lack
58
59 448 of clarity in the case of concurrent other treatment (e.g. chemotherapy) and inconsistencies in
60

1
2
3 449 the vaccination sequence originating from the hospital. At the patient level, comorbid diseases
4
5 450 and poor health as well as associated uncertainties posed an obstacle (e.g. refusing
6
7 451 immunisation during chemotherapy out of fear). Furthermore, GPs stated vaccination delays
8
9 452 due to delivery constraints and named an extra effort of parallel vaccination documentation
10
11 453 (medical alert card for asplenia and vaccination certificate).

12
13
14 454 *'Yes, she suddenly got metastases, she has to have chemotherapy again and so she has*
15
16 455 *insisted that she doesn't get any vaccinations. But that would have all worked out, because I*
17
18 456 *would have had her vaccinated earlier if I had gotten the vaccine.'* [ID072213]

19
20
21 457

22
23 458
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 459 DISCUSSION
4

5 460 This study explored asplenic patients' and GPs' perceptions of a novel intervention aiming to
6
7 461 increase adherence to PSS prevention measures and their experiences in implementation
8
9 462 following this intervention by means of a process evaluation. In our sample there were no
10
11 463 participants whose answers deviated strongly from the general result. The results of both
12
13 464 participant groups therefore provide a relatively homogenous picture and will be discussed
14
15 465 conjointly in the following.

16
17 466 The intervention was overall positively evaluated by both patients and GPs. This referred to
18
19 467 the intervention framework, comprehensiveness and informative value as well as to its
20
21 468 recipient-centeredness, with the telephone based part of the intervention outweighing the
22
23 469 written information material provided. Furthermore, the intervention seemed to have a great
24
25 470 personal relevance for patients and for the attending doctors' professional work. Both groups
26
27 471 reported newly emerged or increased subjective relevant knowledge. This was linked to a
28
29 472 sense of security of being well informed in one's own matter on the part of the patients while
30
31 473 GPs mentioned an increased sense of responsibility in the implementation of precautions and
32
33 474 several practical implications in the asplenic patients' management.

34
35 475 Even though barriers to initial adherence were not an intended focus of the interviews, most
36
37 476 participants referred to it. Both similarities and deviations from relevant studies could be found.
38
39 477 Corresponding to previously reported studies, poor relevant patient knowledge were found[4,
40
41 478 5, 7]. Furthermore, comorbid diseases influenced feasibility of the measures, as well as deficits
42
43 479 in inter-sectorial communication, the latter also being identified as a key barrier for doctor
44
45 480 guideline-conform patient management[4]. However, in comparison to DiSabatino et al.
46
47 481 (2017)[8], who described asplenic patients' concerns about the safety of vaccination or
48
49 482 scepticism about its benefits as barriers to vaccine prophylaxis, these aspects were not
50
51 483 detectable in our interviews.

52
53 484 The intervention, which was theoretically based on the HAPA[12], seemed to be an appropriate
54
55 485 strategy to promote asplenic patients' intention to action, action planning and subsequently, to
56
57 486 improve adherence to prevention measures. Patients portended they developed risk

1
2
3 487 awareness, were convinced, and felt motivated and empowered to plan and implement
4
5 488 preventative measures or demand their initiation from their GPs. It can be suggested that
6
7 489 patients demonstrated self-management behaviour, they presumably did not show before.
8
9 490 Risk awareness was manifested on the cognitive-affective level with a tendency of increased
10
11 491 anxiousness and mental preoccupation or realistic risk estimation and self-efficacy, as well as
12
13 492 in increased health precautionary behaviour and alertness for infection symptoms. Overall, the
14
15 493 results indicate that the targeted prevention measures were mostly implemented appropriately
16
17 494 and in full following the intervention. Subject to the pending quantitative evaluation, we thus
18
19 495 have initial indications that our findings fit in with other research showing the feasibility of
20
21 496 HAPA-based interventions in the context of prevention behaviour[i.a. 13].

22
23
24 497 Our results depict helpful factors and barriers to implementation. As far as helpful factors are
25
26 498 concerned, patients alluded to the social support of their GPs, as well as through relatives.
27
28 499 Patient and GP reported barriers can be divided into patient-attributed, doctor and contextual
29
30 500 or health care system-related factors. Reasons for prolonged or missed vaccination were
31
32 501 comorbidities and related treatments (e.g. chemotherapy) and, very rarely addressed, a
33
34 502 patient's personal refusal. Lack of knowledge, support and education on the part of the GPs
35
36 503 were also negatively contributing factors. Other reasons were at a contextual level, e.g. vaccine
37
38 504 supply constraints, lack of appointment availability or, brought in by GPs, cooperation deficits
39
40 505 between hospital and out-patient care. Since the intervention aimed to address evidenced
41
42 506 barriers, it corresponds with the expectation that in the overall picture, these were disease-
43
44 507 related or structurally given barriers, which could not be addressed by the intervention (e.g.
45
46 508 vaccine availability), that would emerge. Therefore, the qualitative study enabled us to go
47
48 509 beyond the factors addressed in the quantitative part of the study and take context factors into
49
50 510 account, which could be included in future intervention studies and in the actual implementation
51
52 511 of the intervention.

53
54
55 512 The interpretation of all the results must be done bearing in mind that selection bias cannot be
56
57 513 ruled out. As participation in the interviews was a voluntary additional effort, participating
58
59 514 patients and GPs might be a certain subgroup of study participants who tend to be motivated

1
2
3 515 or in favour of the intervention and thus may have induced a positive bias in terms of
4
5 516 intervention evaluation and reported implementation. Furthermore, selection might have
6
7 517 influenced patient-reported barriers (e.g. mostly action-related, rather than personal attitudes
8
9 518 opposing prevention measures). Although the patient selection was purposefully aiming at
10
11 519 maximum variation regarding their pre-interventional adherence ('PrePSS-score'), it must be
12
13 520 further mentioned that very high levels of the PrePSS-score did not occur at all in the sample.
14
15 521 However, we argue that this is less severe, as it represents exactly those patients who are the
16
17 522 target group of our intervention, as the intervention is not urgent for patients with high
18
19 523 adherence scores. Beyond that, it should generally be noted that the prompting of certain
20
21 524 issues during the guideline-based interview might have narrowed or limited the answers given.
22
23
24 525 In conclusion, our findings reveal a positive evaluation and a patient and GP perceived benefit
25
26 526 of the theory-based intervention, thus fulfilling one requirement for a successful implementation
27
28 527 of the intervention. In a next step, the quantitative evaluation of the intervention will be
29
30 528 conducted and recommendations for implementation in usual care will be made on the basis
31
32 529 of the overall evaluation. In the final stage of the project it is planned to provide the relevant
33
34 530 information via our website, congress presentations and publications to GPs and health
35
36 531 insurances to encourage them to implement this successful intervention in real health care
37
38 532 settings.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 534 DECLARATIONS
4
5

6 535 **Funding**
7

8 536 This work was supported by *Innovationsausschuss of Gemeinsamer Bundesausschuss*,
9
10 537 Wegelystraße 8, 10623 Berlin, info@if.g-ba.de (grant number: 01VSF17049). The funding
11
12 538 body was not involved in any aspect of the design of the study, collection of study data, in
13
14 539 writing the manuscript, or in the decision to submit this article for publication.
15
16

17 540 **Competing interests**
18

19 541 None declared.
20
21

22 542 **Author contributions**
23

24 543 Study conception: MG, EF, SR. Development of interview guideline and coding system: NA.
25
26 544 Critical review of the interview guideline and coding system: MB, MG, EF. Data collection and
27
28 545 analysis: NA, MB. Data interpretation: NA, MB, MG, EF, JC. Drafting and revision of the
29
30 546 manuscript: NA. All authors read, contributed to and approved the final manuscript.
31
32

33 547 **Patient consent for publication**
34

35 548 Not required. This manuscript does not contain any patients' individual medical information.
36
37
38

39 549 **Data sharing**
40

41 550 Not applicable.
42
43

44 551 **Ethical approval**
45

46 552 The study was approved by the Ethics Committee of the Albert-Ludwigs-University Freiburg
47
48 553 (No. 380/18, vote from 22 of November, 2018). Informed consent of each patient is obtained
49
50 554 in writing prior to participation.
51
52

53 555 **Acknowledgements**
54

55 556 We would like to thank Dr. Christian Schlett for peer review and comprehensive feedback on
56
57 557 the manuscript. We would also like to thank Rebekka Allen for language editing. Furthermore,
58
59 558 we would like to acknowledge that part of this work has previously been presented at the 20th
60

1
2
3 559 German Conference for Health Services Research: Anka N, Bayrhuber M, Rieg S, et al.
4
5 560 Akzeptanz und Umsetzung einer Intervention zur Infektionsprävention bei Patient*innen ohne
6
7 561 Milz (Asplenie) - Ergebnisse einer qualitativen Interviewstudie [Acceptance and
8
9 562 implementation of an infection prevention intervention in patients without spleen (asplenia) -
10
11 563 results of a qualitative interview study]. *20th German Conference for Health Services.*
12
13 564 Düsseldorf: German Medical Science GMS Publishing House 2021 Doc21dkvf204
14
15 565 (21dkvf204)].

17
18
19 566 **Exclusive Licence**

20
21 567 I, the Submitting Author has the right to grant and does grant on behalf of all authors of the
22
23 568 Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive
24
25 569 licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has
26
27 570 agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US
28
29 571 Federal Government officers or employees acting as part of their official duties; on a worldwide,
30
31 572 perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees
32
33 573 and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish
34
35 574 the Work in BMJ Open and any other BMJ products and to exploit all rights, as set out in our
36
37 575 licence.

38
39 576
40
41 577 The Submitting Author accepts and understands that any supply made under these terms is
42
43 578 made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your
44
45 579 employer or a postgraduate student of an affiliated institution which is paying any applicable
46
47 580 article publishing charge ("APC") for Open Access articles. Where the Submitting Author
48
49 581 wishes to make the Work available on an Open Access basis (and intends to pay the relevant
50
51 582 APC), the terms of reuse of such Open Access shall be governed by a Creative Commons
52
53 583 licence – details of these licences and which Creative Commons licence will apply to this Work
54
55 584 are set out in our licence referred to above.
56
57
58
59
60

585 REFERENCES

- 586 (1) Bianchi FP, Stefanizzi P, Spinelli G, et al. Immunization coverage among asplenic
587 patients and strategies to increase vaccination compliance: a systematic review and
588 meta-analysis. *Expert Rev Vaccines*2021;20:297-308
589 doi:10.1080/14760584.2021.1886085 [published Online First: 14 February 2021].
590
- 591 (2) Theilacker C, Ludewig K, Serr A, et al. Overwhelming postsplenectomy infection: a
592 prospective multicenter cohort study. *Clin Infect Dis*2016;62:871-8
593 doi:10.1093/cid/civ1195 [published Online First: 23 December 2015].
594
- 595 (3) Davies JM, Lewis MP, Wimperis J, et al. Review of guidelines for the prevention and
596 treatment of infection in patients with an absent or dysfunctional spleen: prepared on
597 behalf of the British Committee for Standards in Haematology by a working party of
598 the Haemato-Oncology task force. *Br J Haematol*2011;155:308-317
599 doi:10.1111/j.1365-2141.2011.08843.x.
600
- 601 (4) Lammers AJ, Hoekstra JB, Speelman P, et al. Doctors report barriers to deliver best
602 practice care for asplenic patients: a cross-sectional survey. *PLoS*
603 *One*2011;6:e17302 doi:10.1371/journal.pone.0017302.
604
- 605 (5) El-Alfy MS, El-Sayed MH. Overwhelming postsplenectomy infection: is quality of
606 patient knowledge enough for prevention? *Hematol J*2004;5:77-80
607 doi:10.1038/sj.thj.6200328.
608
- 609 (6) Kealey GP, Dhunge V, Wideroff MJ, et al. Patient education and recall regarding
610 postsplenectomy immunizations. *J Surg Res*2015;199:580-585
611 doi:10.1016/j.jss.2015.05.063 [published Online First: 11 June 2015].
612
- 613 (7) Meerveld-Eggink A, de Weerd O, Rijkers GT, et al. Vaccination coverage and
614 awareness of infectious risks in patients with an absent or dysfunctional spleen in
615 the Netherlands. *Vaccine*2008;26:6975-6979 doi:10.1016/j.vaccine.2008.09.052.
616 [published Online First: 9 October 2008].
617
- 618 (8) Di Sabatino A, Lenti MV, Tinozzi FP, et al. Vaccination coverage and mortality after
619 splenectomy: results from an Italian single-centre study. *Intern Emerg*
620 *Med*2017;12:1139-1147 doi:10.1007/s11739-017-1730-9 [published Online First: 10
621 August 2017].

- 1
2
3 622
4 623 (9) Luu S, Spelman D, Woolley IJ. Post-splenectomy sepsis: preventative strategies,
5 624 challenges, and solutions. *Infect Drug Resist*2019;12:2839-2851
6 625 doi:10.2147/IDR.S179902.
7
8 626
9
10 627 (10) Coignard-Biehler H, Lanternier F, Hot A, et al. Adherence to preventative measures
11 628 after splenectomy in the hospital setting and in the community *J Infect Public*
12 629 *Health*2011;4:187-194 doi:10.1016/j.jiph.2011.06.004 [published Online First: 21
13 630 September 2011].
14 631
15 632 (11) Bayrhuber M, Anka N, Camp J, et al. Prevention of post-splenectomy sepsis in
16 633 patients with asplenia - a study protocol of a controlled trial. *BMC Infect*
17 634 *Dis*2020;20:1-11 doi:10.1186/s12879-019-4752-2.
18 635
19 636 (12) Schwarzer R, Lippke S, Luszczynska A. Mechanisms of health behavior change in
20 637 persons with chronic illness or disability: the Health Action Process Approach
21 638 (HAPA). *Rehabil Psychol*2011;56:161-170 doi:10.1037/a0024509.
22 639
23 640 (13) Zhang CQ, Zhang R, Chung PK, et al. Promoting influenza prevention for elderly
24 641 people in Hong Kong using health action process approach: study protocol. *BMC*
25 642 *Public Health*2018;18:1-9 doi:10.1186/s12889-018-6146-6.
26 643
27 644 (14) Skivington K, Matthews L, Simpson SA, et al. A new framework for developing and
28 645 evaluating complex interventions: update of Medical Research Council guidance.
29 646 *BMJ*2021;374:n2061 doi10.1136/bmj.n2061.
30 647
31 648 (15) Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research
32 649 (COREQ): a 32-item checklist for interviews and focus groups. *Int J Qual Health*
33 650 *Care*2007;19:349-357 doi:10.1093/intqhc/mzm04 [published Online First: 14
34 651 September 2007].
35 652
36 653 (16) Helfferich C. Die Qualität qualitativer Daten: Manual für die Durchführung
37 654 qualitativer Interviews (4. Aufl.). Wiesbaden: VS Verlag 2011:167-193
38 655 doi:10.1007/978-3-531-92076-4.
39 656
40 657 (17) Kuckartz U. Qualitative Inhaltsanalyse: Methoden, Praxis, Computerunterstützung.
41 658 Weinheim: Beltz Juventa 2018.
42 659

- 1
2
3 660 (18) Habersaat KB, Jackson C. Understanding vaccine acceptance and demand - and
4 661 ways to increase them. *Bundesgesundheitsblatt Gesundheitsforschung*
5 662 *Gesundheitsschutz*2020;63:32-39 doi:10.1007/s00103-019-03063-0.
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

COREQ (CONsolidated criteria for REporting Qualitative research) Checklist

A checklist of items that should be included in reports of qualitative research. You must report the page number in your manuscript where you consider each of the items listed in this checklist. If you have not included this information, either revise your manuscript accordingly before submitting or note N/A.

Topic	Item No.	Guide Questions/Description	Reported on Page No.
Domain 1: Research team and reflexivity			
<i>Personal characteristics</i>			
Interviewer/facilitator	1	Which author/s conducted the interview or focus group?	
Credentials	2	What were the researcher's credentials? E.g. PhD, MD	
Occupation	3	What was their occupation at the time of the study?	
Gender	4	Was the researcher male or female?	
Experience and training	5	What experience or training did the researcher have?	
<i>Relationship with participants</i>			
Relationship established	6	Was a relationship established prior to study commencement?	
Participant knowledge of the interviewer	7	What did the participants know about the researcher? e.g. personal goals, reasons for doing the research	
Interviewer characteristics	8	What characteristics were reported about the interviewer/facilitator? e.g. Bias, assumptions, reasons and interests in the research topic	
Domain 2: Study design			
<i>Theoretical framework</i>			
Methodological orientation and Theory	9	What methodological orientation was stated to underpin the study? e.g. grounded theory, discourse analysis, ethnography, phenomenology, content analysis	
<i>Participant selection</i>			
Sampling	10	How were participants selected? e.g. purposive, convenience, consecutive, snowball	
Method of approach	11	How were participants approached? e.g. face-to-face, telephone, mail, email	
Sample size	12	How many participants were in the study?	
Non-participation	13	How many people refused to participate or dropped out? Reasons?	
<i>Setting</i>			
Setting of data collection	14	Where was the data collected? e.g. home, clinic, workplace	
Presence of non-participants	15	Was anyone else present besides the participants and researchers?	
Description of sample	16	What are the important characteristics of the sample? e.g. demographic data, date	
<i>Data collection</i>			
Interview guide	17	Were questions, prompts, guides provided by the authors? Was it pilot tested?	
Repeat interviews	18	Were repeat interviews carried out? If yes, how many?	
Audio/visual recording	19	Did the research use audio or visual recording to collect the data?	
Field notes	20	Were field notes made during and/or after the interview or focus group?	
Duration	21	What was the duration of the interviews or focus group?	
Data saturation	22	Was data saturation discussed?	
Transcripts returned	23	Were transcripts returned to participants for comment and/or	

Topic	Item No.	Guide Questions/Description	Reported on Page No.
		correction?	
Domain 3: analysis and findings			
<i>Data analysis</i>			
Number of data coders	24	How many data coders coded the data?	
Description of the coding tree	25	Did authors provide a description of the coding tree?	
Derivation of themes	26	Were themes identified in advance or derived from the data?	
Software	27	What software, if applicable, was used to manage the data?	
Participant checking	28	Did participants provide feedback on the findings?	
<i>Reporting</i>			
Quotations presented	29	Were participant quotations presented to illustrate the themes/findings? Was each quotation identified? e.g. participant number	
Data and findings consistent	30	Was there consistency between the data presented and the findings?	
Clarity of major themes	31	Were major themes clearly presented in the findings?	
Clarity of minor themes	32	Is there a description of diverse cases or discussion of minor themes?	

Developed from: Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. *International Journal for Quality in Health Care*. 2007. Volume 19, Number 6: pp. 349 – 357

Once you have completed this checklist, please save a copy and upload it as part of your submission. DO NOT include this checklist as part of the main manuscript document. It must be uploaded as a separate file.

Supplemental Material; ANKA et al.

Suppl. Table 1

Interview guideline of patient participants

Welcome and introduction

Introduction of interviewer, aim and procedure of the interview

Interview-questions (*obligatory core questions in bold*)

Evaluation of the telephone intervention (initial question)

Thinking back to the telephone training with the doctor, how did you find that conversation?

How did you feel about the conversation?

What do you remember positively/negatively?

How was the information?

Is there something that would have been helpful for you to know but which did not come up during the phone call? If so, what?

How did you feel about the duration of the phone call?

Experience in implementing the preventative measures

How was the implementation of the preventative measures in your daily life?

What went well? What was easy for you to implement?

Were there any difficulties in implementing some of the precautionary measures? Was anything cumbersome or difficult to implement?

[If yes,] how did that go? What helped you?

Did you discuss these steps with the doctor on the phone beforehand? How was that for you?

What are the next steps concerning the prevention measures?

Dealing with sepsis risk

You have also talked about the increased risk of sepsis with the doctor. How did that go?

Are you now more concerned about developing a sepsis? If yes, why?

Do you feel able to deal with the risk?

Supplementary block: Information material

How do you rate the information material that was sent to you by post?

Conclusion and acknowledgement

Do you want to address something we have not talked about yet?

Supplemental Material; ANKA et al.

Suppl. Table 2

Interview guideline of doctor participants

Welcome and introduction
Introduction of interviewer, aim and procedure of the interview
Interview-questions (<i>obligatory core questions in bold</i>)
Evaluation of the telephone intervention (initial question)
When you think back to the conversation with the doctor from the university hospital, how did you feel about it overall?
What did you like / less like? Do you have any specific improvement suggestions?
How (comprehensible) was the information? Which of the information did you find most (or least) helpful?
Is there something that would have been helpful for you to know, but which did not come up during the phone call? If so, what?
What did you think of receiving the information on the phone? Do you think the written information (without the phone call) would have been sufficient?
How did you feel about the duration of the phone call?
Usefulness of the intervention
Did the information influence your further treatment or education of the affected patient?
If so, how? What information specifically?
If not, for what reason?
Written information material
How do you rate the information material that was sent to you by post?
Online information
The information material included a web address for a website on asplenia. Did you use it and, if so, how? ¹
Expert question
In your view, is there (anything else) that we could improve?
Conclusion and acknowledgement
Do you want to address something we have not talked about yet?

¹ During the telephone intervention, doctors were referred to an asplenia-website for further information. As this aspect is not relevant for the present work, no corresponding results are reported.